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Introduction: Atypical Antipsychotics (AAPs) are approved by the Food and Drug Administration 
(FDA) for the treatment of schizophrenia and bipolar disorder. AAPs are commonly used off-label to 
treat depression, post-traumatic stress disorder and neuropsychiatric symptoms in dementia due to lack 
of alternative treatment options and treatment resistance. Concerns for off-label use arise since AAPs 
increase the risk of cardiovascular events and death. The objectives were 1) describe patterns of RU 
and costs among off-label AAPs users in a nationally representative population 2) identify prevalence 
of off-label use in the Medicare population 3) compare RU and costs between off-label AAPs users 
and non-users with mental health conditions in Medicare.  
Methods: For the first objective, the Medical Expenditure Panel Survey (MEPS) datasets were used. 
AAPs users greater than 18 years were identified in this cross-sectional study. Generalized Linear 
Models (GLM) were used to estimate costs among users and non-users after controlling for age sex, 
gender, insurance type, marriage status, income and comorbidity index. For the second and third 
objective, Medicare datasets were used to identify prevalence, RU, and costs of off-label use in 
    xi 
 
Medicare beneficiaries 18 years and older. RU and costs between propensity score matched AAPs user 
and non-user cohorts were compared in a retrospective cohort study.  
Results: The adjusted odds of having an office-based outpatient (OR=2.47, 95%CI: 1.55-3.92) or 
inpatient (OR=1.63, 95%CI: 1.26-2.10) visit were significantly higher among off-label AAPs users. 
Adjusted office-based visit ($1,943 vs. $1,346), prescription ($4,153 vs. $1,252) and total ($10,694 vs. 
$4,823) costs were significantly higher among users (p<0.0001).  
Among Medicare beneficiaries, approximately 37% of AAPs users had no FDA approved diagnosis. 
The typical off-label user was a white 70-year-old male. Common off-label uses were depression, 
anxiety and neurotic disorders and dementia. Off-label AAPs users had significantly higher mental 
health outpatient ($461 vs $297), prescription ($2,349 vs $282) and total ($3,665 vs $1,297) costs per 
beneficiary than non-users. About 30% of AAPs users had at least one mental health outpatient visit 
during the year versus 23% of non-users; no significant differences were found in inpatient visits. 
AAPs non-users had significantly higher all-cause inpatient costs ($6,945 vs. $4,841) per beneficiary 
(p<0.0001) but there were no differences in total costs. 
Conclusion: In a nationally representative population comprising a younger age group AAPs users 
had higher all-cause RU and total costs than non-users. Off-label prescribing of AAPs continued to be 
a prevalent practice affecting 37% of Medicare AAPs users. Off-label AAPs users had higher mental 
health costs but no significant differences in all-cause total health care costs in a Medicare population. 
Off-label use of AAPs can be a cost-effective option if future research shows off-label use is associated 
with increased effectiveness, which offsets any additional costs. 
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Chapter 1: Introduction and Background 
 1.1 Introduction 
 
Atypical antipsychotics (AAPs) have become the mainstay of treatment for a number of 
mental health disorders. Even though the Food and Drug Administration (FDA) has approved most 
AAPs only for the treatment of schizophrenia and bipolar disorder these drugs are used for other 
mental health conditions such as depression, dementia and post-traumatic stress disorder (PTSD) 
(Maglione et al., 2011). AAPs are now under increasing scrutiny for their increased “off-label” 
use which the FDA defines as, "Use for indication, dosage form, dose regimen, population or other 
use parameter not mentioned in the approved labeling.” Studies have shown that off-label 
prescribing is a common phenomenon in outpatient care and off-label use of AAPs is prevalent in 
different settings and conditions (Leslie et al, 2009; Alexander et al., 2011; Kamble et al., 2010).  
In 2011, the Agency for Healthcare Research and Quality (AHRQ) released a review that 
concluded that most off-label use of AAPs was not supported by moderate to strong evidence but 
at the same time highlighted that not all off-label prescribing may lead to adverse effects (Maglione 
et al., 2011). Concern for off-label use of AAPs arise from their propensity to cause metabolic and 
cardiac adverse effects (McIntyre et al., 2001; Chung & Murray, 2009). Steps, such as a FDA 
black box warning and Centers for Medicare and Medicaid Services (CMS) initiated partnerships, 
have been implemented to decrease off-label use of AAPs specifically in the elderly. 
On the other hand, even though there is concern regarding the use of these agents, 
especially in vulnerable populations, the lack of alternative treatments and treatment resistance 
have paved the way for off-label use among patients with depression, dementia and anxiety 
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(Trivedi et al. 2006; Ravizza et al., 1995; Erzegovesi et al., 2001). Previous studies have shown 
that initiation of off-label use of AAPs in patients with mental health conditions has led to 
decreased hospitalization costs and decreased resource utilization (RU) from pre to post treatment 
since these patients were not seeking treatment for emergent care (Del-Paggio et al., 2002; Lage.& 
Rajagopalan,2006; Al-Zakwani, 2003). The main limitation of these studies was that they focused 
only on a young population primarily with private insurance. The estimates from these studies are 
also not nationally representative and do not focus solely on off-label use of AAPs.  
This study aims to fill the gap in the literature by providing RU patterns and cost estimates 
among off-label AAPs users in a community dwelling population using nationally representative 
data. Secondly, this study also aims to compare RU and costs among AAPs users and non-users 
from a public payer perspective in a population that largely comprises older adults.  
The specific aims and background are provided in the remainder of this chapter. Chapter 2 explores 
the literature that has assessed off-label use of AAPs and its effects on RU and costs. Chapter 3 
presents the methods, results and discussion of a pilot study evaluating national patterns  of 
inpatient, outpatient and emergency visits among off-label AAPs users and non-users in a 
community dwelling population of AAPs users and non-users. Chapters 4, 5 and 6 address the 
methods, results and discussion of a study comparing the RU and costs among AAPs users and 
non-users in the Medicare population.  
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1.2 Specific Aims 
 
Specific Aim I:  
A: Examine RU pattern and estimate costs among off-label AAPs users and non-users in   
     a nationally representative sample  
Specific Aim II: 
 A: Evaluate the prevalence of off-label and on-label use of AAPs and describe patient    
            characteristics in a Medicare population.  
Specific Aim III: 
A: Compare all-cause RU and costs between Medicare beneficiaries using AAPs  
     and those not using AAPs for off-label treatment of mental health conditions.  
B: Compare mental health RU and costs between Medicare beneficiaries using   
     AAPs and those not using AAPs for off-label treatment of mental health conditions. 
Specific Aim IV: 
A: Compare all-cause RU and costs between Medicare beneficiaries using AAPs  
      and those not using AAPs for on-label treatment of mental health conditions.  
B: Compare mental health RU and costs between Medicare beneficiaries using    
     AAPs and those not using AAPs for on-label treatment of mental health conditions. 
Specific Aim V: 
A: Evaluate differences in RU and associated costs in Medicare beneficiaries using AAPs  
     and those not using AAPs to treat specific mental health conditions. 
. 
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1.3 Background 
 
 Pharmacology 
 
Antipsychotic medications have become the mainstay of treatment for a wide variety of 
psychiatric conditions. Second generation antipsychotics or AAPs have become increasingly 
popular as compared to first generation antipsychotics due to their better adverse effect profiles 
(Harrison et al., 2012) and because of their effectiveness in adults (Duggan et al., 2003; 
Srisurpanont et al., 2004; El-Sayeh et al., 2004; Bagnall et al., 2000; Hunter et al., 2003; Davis et 
al., 2003). They are one of the most widely used classes of drugs with sales exceeding $14 billion 
in 2008 and were the top selling drug class in United States in 2008 (Kuehn, 2010). The older 
generation of antipsychotics or the typical antipsychotics are well known for their propensity to 
cause undesirable side effects, primarily extrapyramidal symptoms (EPS), tardive dyskinesia and 
increased prolactin levels (Gardner et al., 2005). The undesirability of these effects and 
irreversibility of certain adverse effects have led to a rapid increase in the use of AAPs over the 
past years.  
This class of drugs work by acting at the dopamine receptors. There are different kinds of 
dopamine receptors that are responsible for a variety of neurological processes. Broadly, the five-
dopamine receptors are D1-D5. The D2 receptor is the site of action for antipsychotics (Mauri et 
al., 2014). Antipsychotics work by blocking the D2 receptor but unlike the first generation 
antipsychotics, the AAPs rapidly dissociate from the D2 receptors therefore leading to lower EPS. 
AAPs also act at certain serotonin receptors and this differential affinity for the different receptors 
makes the individual AAPs unique from each other. For example, AAPs ziprasidone and 
risperidone have high selectivity for both serotonin 5HT2A and D2 receptors, olanzapine and 
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quetiapine have affinity for 5HT2A and D2 receptors in addition to other receptors that are 
cholinergic, histaminergic, and 5HT1A, and aripiprazole is a partial dopamine receptor agonist.  
 Pattern of use 
  
AAPs medications have become the mainstay of treatment for a wide variety of psychiatric 
conditions. There was a rapid increase in their utilization due to low propensity to cause EPS and 
other movement related adverse effects. Even though these agents were originally approved for 
the treatment of schizophrenia and bipolar disorder, they are widely used in the treatment of other 
mental health conditions such as depression, dementia in elderly and others (Maglione et al., 2011).  
Bipolar disorder: AAPs are the main treatment modality for bipolar disorder, either as 
monotherapy or in combination with mood stabilizers. Almost 96.2% of patients who newly 
initiated AAPs were using it as a monotherapy (Chen et al., 2013). Quetiapine, olanzapine and 
risperidone were the most commonly used AAPs for the treatment of bipolar from 2002 to 2008 
among patients newly initiating AAPs (Chen et al., 2013).  
Depression: Data from the National Ambulatory Medical Care Survey (NAMCS) showed 
that the rate of AAPs use increased from 4.6% in 1999-2000 to 12.5% in 2009-2010. The odds of 
using AAPs to treat depression were 2.78 times higher in 2010 compared to 1999 (Gerhard et al., 
2013). Gerhard et al. report that even though some AAPs are approved by the FDA as adjunctive 
treatment for depression in combination with antidepressants, there is a growing use of AAPs for 
non-psychotic depression in the absence of antidepressant therapy.   
Dementia: The non-cognitive symptoms of dementia such as aggression and agitation were 
commonly treated using antipsychotics. In the early 1990s, there was a shift from using the typical 
antipsychotics to the AAPs for the treatment of these symptoms due to their better side effect 
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profile (Lopez et al., 2003). But in the 2000s concern developed over the propensity of AAPs to 
cause diabetes (ADA, 2004) and cerebrovascular effects (Brodarty et al., 2003; Wooltorton , 
2002). As a result, the FDA released a black box warning in 2005: “Treatment of behavioral 
disorders in elderly patients with dementia with AAPs medications is associated with increased 
mortality”. According to a study by Kales et al. which used national Veterans Affairs data, 10.72% 
of patients with dementia were being prescribed AAPs in 1999, and the use increased to 14.4% in 
2003 but then declined to 14.15% in 2005 post the black box warning (Kales, 2011). 
Anxiety: Due to the sedative property of AAPs these drugs have also been considered 
antineurotic and hypnotic medications (Linden & Thiels, 2001). AAPs use for anxiety increased 
from 3.8% in 1996 to 20.5% in 2007 according to a study conducted on NAMCS (Comer et al., 
2011). During the same duration, use of typical antipsychotics decreased from 5.8% to 1.0% 
(Comer et al., 2011). Interestingly, even though AAPs use sharply increased (OR=3.34, p<0.0001) 
during the 12-year time frame, there was only a small increase in the use of FDA approved 
sedative/hypnotics (OR=1.52, p<0.0001). 
Post-traumatic stress disorder (PTSD): Even though AAPs are still being used in the 
treatment of PTSD despite the availability of FDA approved first line treatments, the use showed 
a declining trend from 2002 to 2009 (Bernardy et al., 2012). The overall frequency of use had 
increased from 13.8% to 17.8% in 1999-2002 but declined to 10.4% in 2009 among veterans. 
 Safety concerns with AAPs use 
 
Even though AAPs have a better side effect profile in terms of EPS and other movement 
related disorders, other safety concerns that have risen over the last few years. According to a 
national study that used Healthcare Cost and Utilization Project (HCUP) 2008 data, psychotropic 
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agents were in the top 5 classes of drugs that led to treat-and-release emergency department visits 
and in the top 10 classes that led to inpatient stays due to medication related adverse event (Lucado 
et al., 2011). Evidence from adult studies suggests that AAPs are linked with metabolic 
disturbances; most commonly weight gain, hyperglycemia, diabetes, and hyperlipidemia 
(McIntyre et al., 2001), stroke and cardiac deaths (Chung & Murray, 2009). In this section, the 
adverse effect profile and reasons for safety concerns with AAPs use are explored in detail. 
Metabolic concerns: AAPs have received a lot of attention over the last decade for their 
propensity to cause a myriad of metabolic effects including weight gain, development of Type 2 
diabetes and dyslipidemia. 
- Weight gain: The weight gain associated with AAPs use typically occurs within the first 12 
weeks of initiation of treatment and is believed to be linked with the affinity of the molecule 
to the 5HT2 receptor (Tschoner, 2007). Since olanzapine has the highest affinity for the 
receptor, it is also the agent with the highest weight gain profile (Reynolds & Kirk, 2010). 
Patients using olanzapine gained up to 4.15 kg in 10 weeks (Allison et al., 1999). Even though 
olanzapine users had the highest weight gain, quetiapine and risperidone users have also been 
shown to gain weight but ziprasidone users experienced weight loss in a trial (Lieberman et 
al., 2005).  
- Type 2 diabetes: Due to the propensity to cause maximum weight gain, olanzapine also is also 
associated with an increased risk for treatment-induced type 2 diabetes (Deberdt et al., 2005; 
Newcomer, 2005; Lieberman et al., 2005). Patients developed signs of hyperglycemia as early 
as within 6 weeks of initiation with AAPs (Tschoner, 2007) and 7% of AAPs patients were 
diagnosed with diabetes at the end of one year in a veteran population (Leslie & 
Rosenheck2004).  
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- Dyslipidemia: Olanzapine was also associated with increased risk of dyslipidemia (Deberdt,  
et al., 2005; Newcomer, 2005; Chaggar, 2010). In a double blind clinical trial patients had an 
increase of 12.3 mg/dL total cholesterol levels after 8 weeks of olanzapine (Lindenmayer et 
al., 2003).  
In addition to the metabolic effects in all AAPs users, AAPs are known to be associated with 
other adverse effects that affect the elderly in particular. 
Risk of Death: In 2005, the FDA released a public health advisory based on a meta-analysis of 
17 studies of four drugs (aripiprazole, olanzapine, quetiapine, and risperidone). The meta-analysis 
showed that these studies, which cumulatively enrolled 5,106 elderly patients with dementia, 
showed a 1.6-1.7 fold increase in mortality among AAP users versus non-users (Schneider et al., 
2005). Other studies have reported similar results wherein AAPs users  were associated with higher 
rates of mortality as compared to patients using other psychotropic medications and the risk was 
seen to last over 6-12 months (Kales et al. 2007; Gill et al. 2007; Ray et al., 2009).  
Cerebrovascular Risk: A meta-analysis by Hermann et al. combined the results from 11 trials 
including 11,400 people over the age of 65 who were using risperidone, olanzapine or typical 
antipsychotics. The study showed that that there was an increased risk of cerebrovascular adverse 
events when compared to placebo (Herrmann & Lanctot, 2005). Similar results were reported by 
Douglas et al. There is an increased risk of stroke in patients receiving AAP versus typical agents 
(Douglas & Smeeth, 2008). Other studies reported similar risk of stroke among typical and atypical 
users especially in patients with dementia (Gill et al. 2005; Liperoti et al. 2005; Shin, 2013). 
Cardiac Risk: A recent study by Pariente et al. showed that concurrent antipsychotic (both 
typical and atypical) and cholinesterase inhibitor use led to increased risk of myocardial infarction 
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within 30 days of use, but the risk significantly decreased after 30 days (Pariente et al. 2012). 
Ziprasidone is also known to induce QTc prolongation that can increase the risk of torsade de 
pointes (Glassman & Bigger, 2001). 
Nephrological Risk: According to a new study AAPs can also cause acute kidney injury (AKI) 
in adults aged 65 years and older which could lead to hospitalizations (Hwang et al., 2014). 
Other Risks: Use of certain AAPs in patients with Parkinson’s disease is associated with an 
increased risk of falls and fractures among the elderly. It was found that quetiapine (AOR=2.4), 
risperidone (AOR=1.2) and olanzapine (AOR=1.7) were associated with higher rates of fracture 
(Dore et al., 2009). Bauer et al. also reported that clinical characteristics such as diabetes, 
hyperlipidemia, obesity, and overall cardiovascular risk were associated with use of AAP agents 
in patients with PTSD (P<0.0001) (Bauer et al. 2014). Studies have also found that elderly AAPs 
users have significant risk to develop pneumonia (Trifiro et al., 2010; Star et al., 2010) and deep 
venous thromboembolism (Liperoti et al., 2005). 
Due to these safety concerns, in 2005, FDA required all manufacturers of AAPs to include a 
black box warning on their product label to warn patients about “an increased mortality in elderly 
patients with dementia-related psychoses”. In 2012, the CMS initiated partnerships with multiple 
stakeholders to decrease the off-label usage of AAPs among nursing home residents (Mort et al., 
2014). 
 Off-label Use 
The Food and Drug Administration (FDA) defines off-label use as, "Use for indication, 
dosage form, dose regimen, population or other use parameter not mentioned in the approved 
labeling." Radley et al. showed that off-label prescribing is a common phenomenon in outpatient 
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care and antipsychotics were among the top five classes of drugs for off-label use (Radley et al., 
2006). 
Even though off-label prescribing is not illegal, off-label promotion of drugs by 
manufacturers is. This is in order to prevent drug companies from trying to promote the use of 
drugs for non-FDA approved indications. A number of lawsuits were filed against drug 
manufacturers including Pfizer, Eli Lilly, Bristol-Myers Squibb, Novartis and AstraZeneca within 
the past several years for same (Field, 2010). Majority of the litigation was based on claims that 
the manufacturers promoted the use of AAPs in the elderly population even though the drugs were 
only FDA approved for use in adult patients 18 to 65 years with schizophrenia or bipolar disorder. 
Negative publicity over these large settlements has bought the off-label use of AAPs to the 
forefront. 
In 2011, the Agency for Healthcare Research and Quality (AHRQ) published a systematic 
review of approximately 170 studies and concluded that the most common off-label uses of these 
drugs were for anxiety, dementia in elderly patients, depression, and post-traumatic stress disorder 
(PTSD) (Maglione et al. 2011). Other studies have shown that 60.2% of veterans in 2007, 66% of 
outpatient AAPs users in 2008, and 20.3% of nursing home residents in 2004 used AAPs for off-
label conditions (Leslie et al, 2009; Alexander et al., 2011; Kamble et al., 2010).  
Reasons for Off-label Use 
 
Despite safety concerns, AAPs continue to be used in the treatment of a spectrum of mental 
health conditions and the driving reasons behind this practice are a lack of alternative treatments 
and treatment resistance for many mental health conditions (Tabarrok, 2000). 
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Depression: Current practice guidelines state that patients with depressive disorders should 
be treated using antidepressants (selective serotonin reuptake inhibitors (SSRI), serotonin-
norepinephrine reuptake inhibitor (SNRI), monoamine oxidase inhibitor (MAOI)) in addition to 
psychotherapy (APA, 2010). AAPs should be reserved for patients with severe depression with 
psychotic features. Despite the availability of FDA approved first-line therapy AAPs continue to 
be used as adjunct and monotherapy since 30-40% of depressed patients do not receive any 
significant relief of signs and symptoms after two attempts of antidepressant therapy (Thase et al., 
1998). The STAR*D study reported that only one third of depressed patients had remission after 
a vigorous initial trial of a SSRI (Trivedi et al. 2006). Treatment resistant patients had significantly 
higher health care costs and utilization (Lepine et al., 2012). AAPs have shown to be effective as 
adjunctive treatment for depression (Mahmoud et al. 2007). 
Dementia: Current treatment guidelines state that cholinesterase inhibitors should be 
initiated in patients with mild to moderate dementia (APA, 2014). There are no FDA approved 
treatments for psychotic symptoms. AAPs have been shown to have some effect in decreasing the 
psychotic symptoms associated with personality disorders and neuropsychiatric symptoms of 
dementia (NPSD), neither of which have FDA approved first line treatments (Maher et al. 2011; 
Rosenbluth & Sinyor, 2012). There is an increasing need for pharmacologic interventions to treat 
NPSD in the presence of the rapidly aging baby boomer generation (Maher et al. 2011). 
Anxiety and other neurotic disorders: In addition to psychotherapy, the FDA approved 
certain antidepressants and benzodiazepines for the first line treatment of generalized anxiety, 
panic disorders, phobias and obsessive-compulsive disorder (OCD). Even though 50-60% of 
patients with anxiety respond to their treatment, only one-third to one-half attain full recovery 
during the acute phase (Rickels et al., 2006) similar to 40-60% patients with OCD who failed to 
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respond adequately to treatment with SSRI (Ravizza et al., 1995; Erzegovesi et al., 2001). A 
systematic review suggested that there was some efficacy in using AAPs as augmentation therapy 
in patients with treatment refractory anxiety though the report highlighted the need for more 
rigorous studies (Lorenz et al., 2010).  
PTSD: Current guidelines recommend the use of antidepressants such as sertraline and 
paroxetine for the first-line treatment of PTSD.  AAPs are effective as adjunctive treatment for 
PTSD (Hamner et al., 2003; Petty et al. 2001; Sokolski et al., 2003; Stein et al., 2002), particularly 
in presence of psychotic symptoms (Ahearn et al., 2003). Current treatment guidelines therefore 
recommend the off-label use of AAPs only as adjunctive therapy in patients who have partially 
responded to SSRIs and have psychotic symptoms (APA, 2009). 
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1.4 Rationale 
 
With increasing need and limited resources, it has become imperative to assess appropriate use 
of health care resources and to identify areas of overuse. In psychiatry, AAPs are the cornerstone 
of mental health pharmacotherapy. Even though AAPs are primarily approved for schizophrenia 
and bipolar disorder, there is evidence for efficacy as well as evidence for adverse effects in 
treating indications that are not approved by the FDA such as dementia and depression. Due to the 
varying level of evidence, practitioners have little guidance as to when to prescribe AAPs for off-
label treatment and payers, such as CMS, have little information about the impact of using these 
medications in the off-label treatment of mental health conditions on health care resources.   
The aim of this descriptive study was to estimate the costs and RU associated with using AAPs 
in the off-label treatment of mental health conditions. The results can help inform public policy 
and assist health care professionals in designing health care guidelines targeting specific high-risk 
mental health conditions.  
Our study aims to describe treatment patterns and examine costs during 2008-2010. The CMS 
initiatives to decrease AAPs use have been implemented since 2012 (Mort et al., 2014). Going 
forward, the results of this study will provide baseline RU and costs associated with off-label use 
of AAPs before the regulatory changes were implemented. This will enable us to evaluate the 
changes in treatment patterns, RU and costs after the regulatory changes.   
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Chapter 2: Literature Review  
2.1 Summary of Literature on RU and costs of off-label AAPs Use 
 
A review of the existing body of literature conducted using PubMed/MEDLINE and CINAHL 
used the following search terms: (“Antipsychotic Agents” [Mesh] OR “Atypical Antipsychotics”) 
AND (“Adult” [Mesh]) AND (“Mental Health Services” [Mesh] OR “Resource Utilization” OR 
“Health Care Service”). The following inclusion and exclusion criteria were applied after 
screening through the titles and abstracts: 
Inclusion criteria: 
1. Evaluates health care RU by patients using AAPs for off-label treatment. 
 Exclusion criteria: 
1. Only evaluates RU in patients using AAPs to treat schizophrenia or bipolar disorder. 
2. Studies that are not conducted in the United States. 
3. Studies that assess RU in a pediatric population.  
The search in PubMed and CINAHL initially yielded 431 articles. After screening titles and 
abstracts, removing duplicate articles and applying the inclusion and exclusion criteria, two studies 
were extracted for final review. The references of these two studies were reviewed to evaluate if 
any other studies met the inclusion criteria but were missed during the literature search but no 
additional articles were found from the references. Upon reviewing articles on Google Scholar, 
one more article was found which was not available on the databases.  
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Table 1: Articles included in the summary of literature  
 
Author Comparators Mental health 
conditions 
Data source Outcome Findings 
Lage et al. 
(2005) 
-Olanzapine 
-Quetiapine 
-Risperidone 
-Schizophrenia 
-Bipolar disorder 
-Dementia 
-Depression 
-MarketScan 
commercial claims  
-Hospitalizations 
-Emergency visits 
-Olanzapine and risperidone 
users had higher rates of 
hospitalizations and ED visits 
from baseline to EOS 
-Quetiapine users had lower 
number of hospitalizations and 
ED visits from baseline to EOS 
Al-Zakwani et al. 
(2003) 
 
-Olanzapine 
-Quetiapine 
-Risperidone 
-Clozapine 
-All mental health 
conditions  
(ICD-9-CM: 290-
319) 
-Private claims 
data from a health 
plan 
-Outpatient visits 
-Hospital admissions 
-Hospital outpatient 
visits 
-Emergency visits 
 
-AAPs users were compared to 
typical antipsychotic users and 
AAPs users experienced fewer 
office visits, hospital admissions, 
and ED visits compared to 
typical antipsychotic users 
 
Del Paggio et al. 
(2002) 
 
-Olanzapine -Thought 
disorders 
-Other disorders 
(bipolar disorder, 
depressive 
disorder, OCD, 
PTSD) 
-Large county 
operated mental 
health care system 
-Hospital costs 
-ED costs 
-Medication costs 
-Outpatient costs 
-Patients had significantly 
decreased hospital costs, and ED 
costs in the 12 month follow up 
period from baseline 
-Medications costs and 
outpatient costs increased in the 
olanzapine users from baseline 
to EOS 
*AAPs: Atypical antipsychotics, OCD: Obsessive-compulsive disorder, PTSD: Post-traumatic stress disorder, ED: Emergency department, EOS: 
End Of Study 
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Summary 
 
Lage et al. (2006) 
 
Lage et al. conducted a retrospective study using a large claims database to evaluate 
differences in hospitalizations and emergency department visits among patients with mental illness 
who were initialized on different AAPs. The study utilized the MedStat MarketScan Commercial 
Claims and Encounters (CCE) database (Thomson MedStat). The database includes health related 
data from approximately 100 payers. The dataset contains information on health care utilization 
(inpatient, outpatient, prescription drug and carve-out services) and the associated expenditures.  
Only patients newly initiated on olanzapine, quetiapine or risperidone between July 1, 1998 
and July 2, 2002 were included in the study. The index date was the date of first antipsychotic 
prescription fill. All included subjects had continuous enrollment for the six months before and 
after the index date. The outcomes of interest were the differences in rates of inpatient 
hospitalizations and emergency department (ED) visits between the pre and post index date 
periods.  
Of the 23,778 patients that met the inclusion criteria, 8,730 received olanzapine, 5,709 
received quetiapine and 9,339 received risperidone mostly for schizophrenia, bipolar disorder, 
dementia or depression. The results indicate that for all three antipsychotic drugs, there were 
significant differences in the outcomes between the pre and post period. Patients initiated on 
olanzapine and risperidone had significantly higher RU in the post period as compared to the pre 
period. Olanzapine users had higher rates of hospitalization (2.47% higher), higher ED visit rates 
(3.87%) and an increase in the mean number of hospitalizations by 0.13. Similarly, risperidone 
users had 1.71% and 4.69% more hospitalizations and ED visits respectively and an increase in 
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the mean number of hospitalizations by 0.12. On the other hand, quetiapine users showed 
significantly reduced RU with a 4.37% decrease in hospitalizations and 2.98% reduction in ED 
visits. Upon comparing across the three cohorts of patients who were treated with olanzapine, 
quetiapine or risperidone after controlling for age, gender, region and mental illness diagnosis, 
quetiapine users had significantly lower RU after initiation of therapy. Patients initiated on 
risperidone were also younger and more likely to be male as compared to olanzapine and 
quetiapine users. There were also significant differences among the cohorts with respect to mental 
health diagnoses, olanzapine users were more likely to have bipolar disorder and quetiapine users 
were less likely to be depressed.  
The results of this study indicated that there were differences in the measured RU 
(hospitalizations and ED visits) when comparing the periods before and after initiation of AAPs. 
The results from this study did not provide conclusive evidence of whether initiation of AAPs 
increased or decreased RU among patients since the results varied by the drug used. Patients who 
initiated quetiapine experienced significantly lower RU after initiation but patients using 
olanzapine and risperidone had higher RU in the post initiation period. Since ED visits and 
hospitalizations can drive up the health care costs, the authors point out the importance of 
identifying therapies that can assist in decreasing the costs and improving patient outcomes. In 
previous studies Leal et al. and Dickson et al. reported lower RU after treatment with risperidone 
in patients with schizophrenia (Leal et al., 2004; Dickson et al., 1999) but the study by Lage et al. 
had also included patients with depression and dementia, neither of which is approved to be treated 
with AAPs.  
One of the main limitations of the study was the lack of generalizability of the results. The 
study sample comprised privately insured patients while a large proportion of the population who 
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are diagnosed with mental health conditions have public insurance either via Medicaid or via 
Medicare. The sample also comprised young cohorts of patients with mean age from 37 to 40 
years, therefore the results cannot be extrapolated to an older population who are most vulnerable 
to the adverse effects of AAPs. Other limitations include the inability of the study to capture 
outcomes such as quality of life and functional status of patients due to the nature of the data and 
only evaluating hospitalizations and ED visits as RU.  
 
Al-Zakwani et al. (2003) 
 
Al-Zakwani et al. conducted a study to examine the effects of both atypical and typical 
antipsychotics on healthcare RU. For the study, reimbursement data from a private health plan was 
used which contained information on approximately 500,000 beneficiaries. Only patients between 
six and 65 years of age who had newly initiated an antipsychotic agent between July 1, 1999 and 
September 30, 2000 were included in the study. The date of the first antipsychotic prescription fill 
was the index prescription date (IPD). Only patients who were continuously enrolled in the health 
plan for six months before and 12 months after the IPD were included in the study. Patients were 
categorized as the atypical drug cohort or the typical drug cohort. One of the outcomes of interest 
was RU, which was measured as the number of office-based outpatient, hospital inpatient and 
outpatient, emergency room, and mental health visits. All mental health diagnoses were included 
in the study.  
A total of 469 patients were included in the study of which 82% were AAPs users and only 
18% were using typical antipsychotics. Majority of the patients were using the medications to treat 
some form of psychosis (79%) and neurosis (42%). Some of the other main mental health 
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conditions included drug and alcohol dependence, depressive disorders, and mental disorders of 
childhood origin.  
As compared to the typical drug class users, AAPs users experienced 45% fewer office 
visits, 76% fewer hospital admissions, 41% fewer hospital outpatient visits and 67% fewer 
emergency room visits after controlling for age, gender, medication possession ratio (MPR), length 
of therapy, treatment augmentation and switches. The mean age of the AAPs users was only 34 
years and almost 75% were prescribed concomitant antidepressants.  
The result of this study indicate AAPs users have lower hospital admission rates and office-based 
outpatient and emergency visits over the one-year period after initiation of AAPs compared to 
typical antipsychotic users. The major strength of this study is that it assessed RU among all mental 
health disorders and did not exclude patients who were using AAPs for off-label treatment. The 
authors also note that AAPs users had higher rates of concomitant psychotropic drug use such as 
antidepressants and mood stabilizers and this association could drive down the rates of RU. 
As with the study by Lage et al. this study used data from a private health insurance plan 
therefore the results are only generalizable to a population comprising private health plan 
beneficiaries and not to patients who have public insurance. Another major limitation is that the 
study explicitly stated that patients over 65 years were not included in the study. Therefore, even 
though this study assessed RU among off-label AAPs users, the results cannot be extrapolated to 
an elderly population who are more prone to the adverse effects of AAPs. The authors note other 
limitations due to the retrospective nature of the study and secondary database. Confounding due 
to unobserved factors such as physician’s justification for selection of different therapies and 
selection bias are also limitations to the study.  
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Del Paggio et al. (2002) 
Del Paggio et al. conducted a study within the Alameda County Behavioral HealthCare 
Services (BHCS) which is a non-profit organization located in California. The BHCS serves 
approximately 1.4 million residents, provides community-based treatment for the severely 
mentally ill patients, and covers all services such as inpatient hospitalization, emergency 
services, residential treatment, outpatient services and medications. All outpatients who received 
coverage by BHCS and began olanzapine treatment between November 1, 1996 and April 30, 
1998 were included in the study. Economic and RU data were collected from the Insyst database 
(countywide system maintained by BHCS) and the Pharmaceutical Care Network’s 
MedIntelligence Access Database (a pharmaceutical benefits management company that was 
contracted to automate the pharmacy providers within the county network). The date of the first 
olanzapine fill was the index date and only patients continuously enrolled 12 months before and 
after the index date were included in the study.  
One hundred and eighty nine patients were identified in the BHCS system who had been 
initiated on olanzapine during the study period. The mean age of the patients was approximately 
36 years reflective of a younger population. Majority of the patients (66%) had diagnosis for 
thought disorders whereas the other 34% comprised patients with bipolar disorder, depressive 
disorder, obsessive-compulsive disorder, adjustment reactions and post-traumatic stress disorder. 
Of the 189 patients, 78 continued olanzapine therapy for 12 months or switched to another agent. 
These patients had significantly decreased hospital, and emergency costs in the 12 month follow 
up period. There was a mean decrease of $4,423 per patient in hospital costs and $203 per patient 
in emergency costs from before the index date to after the index date. On the other hand, 
medications costs significantly increased by $1,585 per patient. Even though the individual 
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components showed significant changes, the overall RU difference was non-significant with a 
mean decrease of $1,991 per patient. Among the 58 patients who continued olanzapine therapy for 
the 12 months there were significant decreases in the hospital and emergency costs but significant 
increases in the medication and outpatient costs.  
The results of this study indicated a significant decrease in hospital and emergency costs 
even though it failed to achieve significance in total RU. Olanzapine users incurred increased 
medication and outpatient costs but this was offset by the decrease in hospital and emergency 
visits. The study results indicated that olanzapine users were able to achieve positive clinical 
outcomes through decreased Positive and Negative Syndrome Scale (PANSS) and the declining 
RU suggesting that off-label treatment of mental health conditions with olanzapine could be cost-
effective.  
Several limitations existed with this study. First, the authors note that there could have been 
undetected or unaccounted changes in the health care policy that they were unaware of which could 
have resulted in decreased RU. Second, the population included in the study was eligible to receive 
treatment through the BHCS because of the severity of illness, therefore it may be relatively easier 
to show clinical improvement and decreased RU. Another limitation stated by the authors is the 
lack of control group due to which one cannot establish causality between olanzapine use and the 
decreased RU.  
Apart from the limitations stated by the authors, the study also lacks generalizable results 
since the study consists of severely ill patients who are eligible to receive state provided financial 
coverage in one small health system in California. These patients are a small subset of the 
population and therefore the results cannot be extrapolated to a larger population. As with the 
previous studies, the sample also consisted primarily of a young group of patients. Despite the 
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limitations, the study does provide evidence that olanzapine use shifts costs away from 
hospitalization and emergency costs towards medication and outpatient costs. 
 The three studies that have evaluated RU among off-label AAPs users have found mixed 
results. One study showed that RU varied by the specific AAPs used with quetiapine being the 
preferred drug of choice to decrease hospitalizations and emergency department visits (Lage et al., 
2006). The other two studies concluded that AAPs use does decrease inpatient and emergency 
visits but reached different conclusions regarding outpatient visits. Al-Zakwani et al. reported 
lower outpatient visits while Del Paggio et al. reported an increase in the number of outpatient 
services and costs.  
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2.2 Gaps in Literature 
 
To the best of our knowledge, there are only three studies that have assessed RU among those 
who are using AAPs for off-label treatment of mental health conditions. All used data from private 
claims data or from a specific county operated mental health care system. By using data from 
private sources, the results are only applicable to a similar segment of the population. None of the 
studies evaluated RU from a public payer perspective.  
Another gap in the literature is that all the studies either exclusively included patients less than 
65 years of age or had minimal patients over 65 years of age since the source of data was private 
payers and not Medicare. As discussed in the earlier section, elderly patients over 65 years are 
most vulnerable among adults to the adverse effects of AAPs and this cohort of patients are usually 
excluded from studies. There is a need to conduct studies that focus on elderly AAPs users and 
assess RU pattern and risks in this cohort. 
Another feature common to all three studies is that none of them evaluated RU solely among 
off-label AAPs users. The studies included patients with a myriad of mental health conditions 
including schizophrenia and bipolar disorder for which treatment with AAPs is FDA approved. 
No study has assessed RU among patients who are solely using the AAPs for off-label treatment. 
Finally, as mentioned earlier, all three studies used data from private sources and therefore the 
results are not generalizable to a large population.  
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Chapter 3: Resource Utilization Patterns and Costs Associated with Off-label 
Use of AAPs in a Community-Dwelling Adult Population 
 
Specific Aim I: Examine RU patterns and estimate costs among off-label AAPs users 
and non-users in a nationally representative sample 
3.1 Methods 
 
Study Design: A retrospective cross-sectional study was conducted using a publicly 
available national database to compare RU and costs among respondents using AAPs off-label to 
treat mental health conditions to those not using AAPs. 
Data Source: This retrospective study was done using Medical Expenditure Panel Survey 
(MEPS) data that is sponsored by the Agency for Healthcare Research and Quality (AHRQ). 
MEPS is a nationally representative survey of civilian non-institutionalized US individuals and 
households, that collects information on patient demographics, employment, income, access to 
health care, health care use, medical expenditures, insurance coverage and sources of payment. 
MEPS can be used to produce national estimates of health care RU and expenditures. Household 
survey data are collected by computer-assisted personal interviews. Each year MEPS enrolls a new 
sample of households which is followed for 2.5 years over five interviews. This study utilized the 
household component of the MEPS data from 2009-2013. Five years of data were pooled to 
increase the sample size and reduce the standard error of the estimates. Since each year represents 
a nationally representative sample for that given year, respondents were included twice if they 
completed all five panel interviews during the span of two consecutive years. Even though this led 
to correlation in the data from year to year, specifying the stratum and the primary sampling unit 
(PSU) in the variance estimation accounted for any correlation. All information on patient 
 25 
 
characteristics, RU and costs were obtained from the Full-Year Consolidated files, information on 
chronic conditions was obtained from the Medical Conditions files and information on medication 
use was obtained from the Prescribed Medicines event files. 
Study sample: The study included all MEPS respondents 18 years and older who reported 
a diagnosis for a mental health condition for which treatment with AAPs would be off-label. That 
is, all patients with schizophrenia or bipolar disorder were excluded. In this study, mental health 
conditions were identified using the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM). Since only schizophrenia (ICD-9-CM: 295) and bipolar 
disorder (ICD-9-CM: 296) have received approval to be treated with AAPs, all other mental health 
conditions (ICD-9-CM: 290-319) were defined as conditions for which treatment with AAPs 
would be off-label and were included in the study sample.  
Exposure: The study sample was categorized into users and non-users based on their AAPs 
use. Respondents were categorized as users if they had at least two claims for an AAP within the 
same year. AAPs medications were identified using the therapeutic sub-classification variable 
(TC1S1_1) in the Prescribed Medicines file. 
Independent variables: The primary independent variable was AAPs use. Covariates 
included age, gender, race, education, marital status, insurance, income level and the Charlson 
Comorbidity Index (CCI) score. The demographic variables were categorized as following: age in 
two categories of 18-64, 65 and older; race in three categories of White, Black and other; education  
in three categories of high school or less, some college or more and never went to school; marital 
status in four categories of married, widowed, divorced/separated, and never married; insurance in 
three categories of private, public and uninsured; and income level in four categories of poor, low, 
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medium and high. Comorbidities were measured using the CCI, a continuous variable, which was 
calculated using ICD-9-CM codes.  
Outcomes: The primary outcome of interest in the study was select RU (office-based 
medical provider visits, outpatient visits, inpatient visits and emergency room visits) for the given 
year. The secondary outcome of interest was the person-level mean health care expenditure per 
year. Drug expenditures were included in the expenditure variable. In MEPS, expenses are defined 
as payments for care from all sources. These include patient out-of-pocket and all third party payers 
(e.g., Medicare, Medicaid, private insurance, others).  
Statistical analyses: Demographic characteristics of AAPs users and non-users were 
compared using chi-square tests. The unadjusted mean RU and expenditures for users and non-
users were compared using t-tests. Multivariable logistic regression models were used to assess 
the association between AAPs use and RU. Several regression models were developed to model 
overall RU, inpatient use, office-based medical provider use, outpatient use and emergency room 
use. The variables controlled for in the regression models included age, gender, race, education, 
marital status, insurance, income and CCI.  
Generalized linear model (GLM) was used to estimate the adjusted medical costs 
associated with off-label use of AAPs. Due to the presence of excessive zero costs and highly 
skewed data, traditional ordinary least square (OLS) estimates are ineffective in modeling costs 
data. Even though log-transformed OLS can account for skewed data, the retransformation to the 
original scale makes interpretation of the estimates difficult. Additionally, heteroscedasticity in the 
data might also lead to biased estimates. Therefore a GLM model with the appropriate link function 
is more appropriate to model cost data as it relaxes the assumptions of normality and 
homoscedasticity. A GLM with gamma distribution and a log link was used to estimate costs. 
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Since the number of observations with zero costs was less than 6% in our study a 2-part model 
was not used.  
To generate national estimates, the complex sampling design of the MEPS dataset was 
taken into account by using person-level weights, primary sampling unit and variance estimation 
strata. All statistical analyses were conducted using SAS software version 9.4 (SAS Institute, Cary, 
NC) and STATA software version 12. A p-value < 0.05 was considered statistically significant. 
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3.2 Results 
 
Of the survey respondents in 2009-2013, 18,246 (weighted N= 40,939,089) respondents 
were adults 18 years and older who reported being diagnosed with an off-label mental health 
condition. This sample of MEPS respondents had positive weights and was included in the final 
analysis. Of these, 3.5% (weighted n=1,422,307) were AAPs users and the remaining 96.5% were 
non-users (Figure 1).  
 
 
Study population characteristics: Table 2 reports the demographic characteristics of 
survey respondents included in the study. Statistical differences among users and non-users were 
found for race, education, marital status, insurance, income level and the CCI score.  AAPs users 
were more likely to be black (15.80%), high school educated or less (55.64%), never married 
(34.31%), with public insurance (46.41%) and poor income (37.09%) as compared to the non-
users. The CCI score was significantly higher (1.24+0.05) among users.  
 
 
AAPs Users, 
3.50%
AAPS Non-
users, 96.50%
Figure 1: Prevalence of AAPs use in respondents 
without FDA approved indications
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Table 2: Demographic characteristics of study population 
Characteristic AAPs users (%) 
(Unweighted N =770) 
 (Weighted N=1,422,307) 
AAPs non-users (%) 
(Unweighted N=17,476) 
(Weighted N=39,516,782) 
p-value 
Age 
   18-64 
   65+ 
 
82.36 
17.64 
 
79.88 
20.12 
0.2904 
Gender 
   Male 
   Female 
 
40.77 
59.23 
 
36.36 
63.64 
0.1561 
Race 
   White 
   Black 
   Other 
 
79.34 
15.80 
4.86 
 
88.07 
7.18 
4.75 
<0.0001 
Education  
   High school or less 
   Some college or more 
   Never been to school 
 
55.64 
43.36 
1.00 
 
43.22 
56.62 
0.16 
<0.0001 
Marital Status 
   Married 
   Widowed 
   Divorced/separated 
   Never married 
 
30.86 
11.11 
23.72 
34.31 
 
48.00 
8.42 
19.81 
23.77 
<0.0001 
Insurance 
   Private 
   Public 
   Uninsured 
 
47.04 
46.41 
6.55 
 
66.80 
22.90 
10.30 
<0.0001 
Income 
   Poor 
   Low 
   Medium 
   High 
 
37.09 
16.58 
22.25 
24.08 
 
19.55 
13.63 
30.18 
36.64 
0.0001 
CCI (SE) 1.24 (0.05) 1.05 (0.01) 0.0007 
Abbreviation used: CCI, Charlson Comorbidity Index 
 
Unadjusted RU and costs in off-label AAPs users: Respondents using AAPs had more 
office-based provider visits, emergency room visits and inpatient visits, and higher mean office-
based provider, inpatient, prescription and total costs compared to non-users (Table 3). Users were 
estimated to have unadjusted mean total costs of $15,157 per respondent relative to non-users of 
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$7,304 (p<0.0001).  Therefore, the total cost for people 18 years and older with an off-label mental 
health condition using AAPs (weighted N=1,422,307), was estimated to be $21.5 billion. 
Table 3: Mean utilization and expenditures among respondents by AAPs use 
Utilization Measure (#) AAPs users 
Mean (SE) 
AAPs non-users 
Mean (SE) 
p-value 
Office based provider visits 15.1 (1.02) 9.93 (0.19) <0.0001 
Outpatient visits 1.20 (0.26) 0.84 (0.05) 0.1875 
Emergency room visits 0.49 (0.05) 0.33 (0.01) 0.0022 
Inpatient visits 0.37 (0.05) 0.17 (0.01) <0.0001 
    
Expenditure Measure ($) AAPs users 
Mean (SE) 
AAPs non-users 
Mean (SE) 
p-value 
Office based provider visits 2,474 (186) 1,953 (47) 0.0063 
Outpatient visits 844 (144) 673 (37) 0.2562 
Emergency room visits 437 (72) 311 (11) 0.0800 
Inpatient visits 4,887 (900) 2,223 (98) 0.0033 
Prescription  6,516 (423) 2,144 (5) <0.0001 
Total 15,157 (1226) 7,304 (151) <0.0001 
Abbreviation used: SE, standard error 
Adjusted RU in off-label AAPs users: After adjusting for covariates, off-label AAPs user 
was associated with greater resource utilization (Table 4). The odds of having an office based 
outpatient or inpatient visit were significantly higher among respondents who used AAPs off-label 
to treat their mental health conditions as compared to respondents not using AAPs. The odds of 
using any health care resource among users were also twice the odds of non-users (p=0.0006).  
Table 4: Adjusted regression model estimates for resource utilization by AAPs use  
Resource Utilization OR Lower 95%CI Upper 95% CI p-value  
Office based outpatient visits  2.47 1.55 3.92 0.0001 
Outpatient visits 1.28 0.96 1.71 0.0873 
Emergency room visits 1.09 0.87 1.38 0.4476 
Inpatient visits 1.63 1.26 2.1 0.0002 
Any utilization  2.42 1.46 4.03 0.0006 
Abbreviation used: OR, odds ratio; CI, confidence interval 
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Adjusted costs in off-label AAPs users: Office based visits and prescription costs were 
found to be significantly higher among those using AAPs as compared to non-users (p<0.0001). 
Inpatient and prescription costs were the major contributors to costs.  
Table 5: Adjusted cost estimates for respondents with off-label mental health conditions 
Resource Utilization AAPs Users AAPs non-users p-value 
Mean ($) SE Mean ($) SE 
Office based outpatient 
visits  
1,943 189 1,436 107 <0.0001 
Outpatient visits 1,632 324 1,457 235 0.4255 
Emergency room visits 1,722 280 1,438 122 0.1935 
Inpatient visits 
24,543 4580 18,839 2372 0.0643 
Prescription   4,153 354 1,252 88 <0.0001 
 
 
3.3 Discussion 
 
The sample used in these analyses was MEPS respondents greater than 18 years with 
mental health conditions not approved by the FDA to be treated with AAPs. Based on this study, 
3.5% of the non-institutionalized US population with conditions other than schizophrenia or 
bipolar disorder was AAPs users. The typical AAPs user was a 18-64 year old white female with 
a high school education, never married with a very low income. Compared to those not using 
AAPs, users also had higher proportion of respondents who were on public insurance and had 
higher comorbidity index. These results were similar to what was reported by Domilano & Swartz 
in a study which examined changes in prevalence of AAPs use from 1996/1997 to 2004/2005 in a 
MEPS sample. The study reported AAPs users to be primarily 18-64 year old, white females with 
low family income and public insurance (Domilano & Swartz, 2008). 
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 This study found that AAPs users had higher odds of having an office-based outpatient and 
inpatient visit after adjusting for covariates age, gender, race, education, income, insurance, 
marriage status and comorbidity index. Users also had higher odds of having any RU as compared 
to non-users. Office based visit costs and prescription costs were found to be significantly higher 
among AAPs users as compared to non-users (p<0.0001). 
 These results were not similar to what was reported in the study by Al-Zakwani et al. in a 
private health plan sample comprised 6 to 65 year olds with any mental health conditions (Al-
Zakwani et al., 2003). They reported AAPs users to have fewer office visits, hospital admissions, 
and hospital-based outpatient visits compared to those using typical AAPs. These differences could 
be due to the different sample (private health plan beneficiaries’ vs.  survey respondents) and 
different comparator groups (typical antipsychotic users vs. respondents with mental health 
conditions without AAPs claims). In the study by Lage et al., the authors found that among 
individuals with dementia, depression, schizophrenia and bipolar disorder, patients using 
olanzapine and risperidone experienced significantly higher rates of hospitalizations and 
emergency room visits from baseline to post treatment and patients using quetiapine experienced 
significantly lower hospital admission rates and emergency visits from baseline to post treatment 
(Lage et al., 2006). Our study reflects the pattern that was observed in the olanzapine/risperidone 
cohort but no conclusions can be determined until the RU pattern by AAPs agent is determined.  
 Even though AAPs use has evidence for efficacy in patients with schizophrenia and bipolar 
disorders (Maglione et al., 2011) and may improve quality of life due to lower risk of EPS and 
related disorders, these benefits may be overshadowed by their propensity to cause metabolic risks 
(Gareri et al., 2014). Therefore the use of these agents in treating conditions not FDA approved or 
backed by evidence such as OCD and PTSD, may only further increase health care RU and costs. 
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With increasing affordability as more of these drugs come off patent, there could be a further 
increase in the rate of use of AAPs to treat off-label mental health conditions. 
On the other hand, restrictive policies introduced by regulatory bodies, such as the CMS 
partnerships to decrease AAPs use in elderly population, aim to decrease the use of AAPs 
especially in a vulnerable population. These steps are backed by the premise that most off-label 
use is not backed by clinical evidence. Even though these steps are undertaken to ensure the safety 
of the patients, it raises the question of whether these policies are also restricting access to much 
needed medications for certain patients.  
Limitations 
This study provided an initial insight into the pattern of RU and costs among off-label AAPs users 
in a non-institutionalized US population.  GLM was used to describe costs controlling for 
differences between users and non-users. There are also some limitations in the study. First, the 
cross-sectional study design does not help establish causality; it can only identify an association 
between off-label AAPs use and higher RU and costs. It is therefore important to conduct a 
longitudinal cohort study design to establish a causal relationship. Second, the users and non-users 
were different in their baseline characteristics since this was not a randomized controlled trial. We 
tried to address this limitation within the scope of the project by controlling for such variables in 
the regression models even though we could not control for variables such as severity of disease. 
Third, since MEPS is collected from self-reported surveys, there is the possibility of selection and 
recall bias. Since mental health conditions are often associated with stigma, patients may 
underreport the presence of these conditions. This could potentially underestimate the prevalence 
of mental health conditions despite the presence of medication claims. On the other hand, patients 
who are active participants in their health may be more likely to be a MEPS respondent leading to 
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selection bias. Fourth, MEPS data only allows for identification of ICD-9 codes up to three digits; 
therefore patients with bipolar disorder and depression (identified using ICD-9-CM: 296) were 
grouped in one category thereby overestimating the FDA approved use. A longitudinal study using 
claims data (described in the next section) was done to address some of these limitations.  
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Chapter 4: Methods 
 
This chapter describes the methods used to address specific aims II, III, IV and V. It includes 
details on data source, study design, study population, variables and statistical analyses. 
Data source 
The data used in this project was obtained from the Centers for Medicare and Medicaid 
Services (CMS). The study employed data from 2008 to 2010 Chronic Condition Data Warehouse 
(CCW) Medicare files which are managed by the Research Data and Assistance Center (ResDAC). 
A random sample of one million beneficiaries and their beneficiary summary, inpatient, outpatient 
and prescription claims were used in the study. Beneficiary information was de-identified and a 
unique patient identification number was used to link the beneficiaries across files.  
This particular data source was used for this study since Medicare is a good source of 
information for people over 65 years. Using Medicare data enables capturing real data on an elderly 
population who are normally excluded from adult studies and adults over 18 years who are eligible 
for Medicare due to their disability. Additionally, the use of a claims database removes the 
potential for recall and self-reported bias that are associated with survey data. 
A number of files were used to meet the study objectives. The Master Beneficiary 
Summary File (MBSF) was used to identify demographic and enrollment eligibility information. 
The inpatient, outpatient and prescription drug event (PDE) files were used to identify claims for 
RU and to compute costs. The CCW Chronic Conditions File and Other Chronic Conditions file 
were used to identify comorbidities including mental health conditions. The files and the variables 
that have been used are described below. 
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Table 6: Master Beneficiary Summary File (MBSF) 
SAS Variable Name Description 
BENE_ID An unique encrypted beneficiary identification number that was 
used to link the beneficiaries across files 
AGE Beneficiary’s age at the end of the year 
SEX Beneficiary’s gender 
RACE Beneficiary’s race was categorized as White, Black and Others 
ESRD_IND Indicator of End-stage Renal Disease (ESRD) 
CREC Current reason for Medicare entitlement, used to identify 
beneficiaries with disabilities 
A_MO_CNT Count of months with Part A coverage, used to identify 
continuous Part A enrollment 
B_MO_CNT Count of months with Part B coverage, used to identify 
continuous Part B enrollment 
PLNCOVMO Count of months with Part D coverage, used to identify 
continuous Part D enrollment 
CNTRCT Type of Part D contract, used to identify those with stand-alone 
drug plan to serve as proxy for fee-for-service beneficiaries 
HMO_MO Number of months of HMO coverage, used to identify 
beneficiaries with fee-for-service versus HMO coverage 
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Table 7: Inpatient and Outpatient files 
SAS Variable Name Description 
BENE_ID An unique encrypted beneficiary identification number that was 
used to link the beneficiaries across files 
CLM_ID Unique encrypted claim identification number used to identify 
duplication of claims 
PMT_AMT Amount paid by Medicare for the services covered by claim 
UTIL_DAY Number of days utilized by claims, used in calculating amount 
paid by Medicare not included in the claim payment amount 
PER_DIEM Pass through amount not included in the claim payment amount 
PRPAYAMT Amount paid by primary payer if not Medicare 
DED_AMT Beneficiary deductible amount 
COIN_AMT Beneficiary coinsurance amount 
BLDDEDAM Beneficiary blood deductible liability amount 
ADMTG_DGNS_CD Admitting diagnosis ICD-9-CM code 
PRNCPAL_DGNS_CD Primary diagnosis ICD-9-CM code 
ICD_DGNS_CD1-25 Claim diagnosis code 
 
 
 
 
 
  
 38 
 
Table 8: Part D Event (PDE) file 
SAS Variable Name Description 
BENE_ID An unique encrypted beneficiary identification number that was 
used to link the beneficiaries across files 
PDE_ID Unique encrypted prescription claim identification number used 
to identify duplication of claims 
SRVC_DT Date of service of prescription claim 
PTPAYAMT Amount paid by patient for claim 
CPP_AMT Amount paid by Medicare for claim 
GNN Generic name of drugs 
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Table 9: MBSF Chronic Conditions and Other Chronic Conditions files 
SAS Variable Name Description 
BENE_ID An unique encrypted beneficiary identification number that was 
used to link the beneficiaries across files 
AMI Acute myocardial infarction 
ALZ Alzheimer’s disease 
CHRNKIDN Chronic kidney disease 
COPD Chronic obstructive pulmonary disease 
CHF Congestive heart failure 
DIABETES Diabetes Mellitus 
RA_OA Rheumatoid and Osteoarthritis 
CNCRBRST Breast cancer 
CNCRCLRC Colorectal cancer 
CNCRPRST Prostate cancer 
CNCRLUNG Lung cancer 
DEPRESSN Depression 
ANXI_MEDICARE Anxiety disorders 
AUTISM_MEDICARE Autism spectrum disorders 
BIPL_MEDICARE Bipolar disorder 
ACP_MEDICARE ADHD, conduct disorders and hyperkinetic syndrome 
INTDIS_MEDICARE Intellectual disabilities and related conditions 
LEADIS_MEDICARE Learning disabilities 
OTHDEL_MEDICARE Other developmental delays 
PSDS_MEDICARE Personality disorders 
PTRA_MEDICARE Post-traumatic stress disorder 
SCHI_MEDICARE Schizophrenia 
SCHIOT_MEDICARE Schizophrenia and other psychotic disorders 
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Approvals 
The proposal for this project was approved by the Virginia Commonwealth University 
institutional review board (IRB) under expedited review. In addition, the proposal was also 
approved by ResDAC and CMS.  
4.1 Specific Aim II 
 
Specific Aim II: Evaluate the prevalence of off-label and on-label use of AAPs and describe 
patient characteristics in a Medicare population. 
 
Study design 
A retrospective, cross-sectional study was employed using Medicare secondary databases 
to compute the prevalence of off-label and on-label use of AAPs. AAPs users were identified and 
the prevalence of off-label and on-label use in 2008, 2009 and 2010 was computed.  
Population of interest 
For the first Specific Aim, the population of interest was AAPs users 18 years and older 
within each year. Beneficiaries were considered to be AAPs users if they had at least two claims 
(>1 day and < 60 days apart) for AAPs during the year. A minimum of two claims for the same 
agent was chosen to eliminate beneficiaries who had been given a one-time dose as part of their 
emergent care. Only AAPs with registered National Drug Codes (NDC) numbers before January 
1, 2008 were included in the study. The drugs and their FDA approved indications have been 
denoted in Table 10 as obtained from the FDA website  
https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ 
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  Table 10: List of atypical antipsychotics agents of interest   
Drug Name FDA approved indications before January 1, 2008 
Olanzapine (Zyprexa) -Oral: Schizophrenia, Bipolar disorder (monotherapy and 
in combination with lithium or valproate) 
-IM: agitation associated with schizophrenia or bipolar 
mania 
Quetiapine (Seroquel) Schizophrenia, Bipolar disorder (Depression, mania, 
maintenance) 
Risperidone (Risperdal) Schizophrenia, Bipolar (manic or mixed) disorder 
(monotherapy and in combination with lithium or 
valproate) 
Aripiprazole (Abilify) Schizophrenia, Bipolar (Manic or mixed), adjunctive 
therapy to Major Depressive disorder (adjunct to AD) 
Ziprasidone (Geodon)  Oral: Schizophrenia, Bipolar Mania 
IM: Acute agitation in schizophrenic patients 
IM: Intra-muscular AD: Anti-depressants 
Off-label use: For this study, an indication-based definition of off-label use was applied 
i.e., indications that were not approved by the FDA to be treated with AAPs were categorized as 
off-label use. All the AAPs of interest have been approved by the FDA for the treatment of 
schizophrenia and bipolar disorder. Therefore use of AAPs in absence of these two indications was 
deemed off-label use. Claims for mental health conditions were identified using the International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. These 
diagnosis claims were identified from the principal diagnosis, admitting diagnosis or any of the 25 
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ICD-9-CM variables in the inpatient and outpatient file or from the Other Chronic Conditions file. 
All AAPs users who had at least one inpatient or two outpatient claims for schizophrenia (ICD-9-
CM: 295.xx) and/or bipolar disorder (ICD-9-CM: 296.0, 296.1, 296.4 – 296.9) were classified as 
FDA approved or on-label users. All other AAPs users were considered off-label users.  
 
Statistical Analysis 
Descriptive analysis of the study population was conducted. Continuous variables were 
described using means and standard deviation and categorical variables were described using 
counts and percentages. Prevalence of off-label and on-label use of AAPs for each year was 
calculated as follows: 
 
𝑂𝑓𝑓𝑙𝑎𝑏𝑒𝑙 𝑈𝑠𝑒 = 100 𝑋 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑛𝑒𝑓𝑖𝑐𝑖𝑎𝑟𝑖𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑆𝑐ℎ𝑖𝑜𝑝ℎ𝑟𝑒𝑛𝑖𝑎 𝑜𝑟 𝐵𝑖𝑝𝑜𝑙𝑎𝑟 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑛𝑒𝑓𝑖𝑐𝑖𝑎𝑟𝑖𝑒𝑠 𝑢𝑠𝑖𝑛𝑔 𝐴𝐴𝑃𝑠
 
 
 
𝑂𝑛𝑙𝑎𝑏𝑒𝑙 𝑈𝑠𝑒 = 100 𝑋 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑛𝑒𝑓𝑖𝑐𝑖𝑎𝑟𝑖𝑒𝑠 𝑤𝑖𝑡ℎ 𝑆𝑐ℎ𝑖𝑜𝑝ℎ𝑟𝑒𝑛𝑖𝑎 𝑜𝑟 𝐵𝑖𝑝𝑜𝑙𝑎𝑟 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑛𝑒𝑓𝑖𝑐𝑖𝑎𝑟𝑖𝑒𝑠 𝑢𝑠𝑖𝑛𝑔 𝐴𝐴𝑃𝑠
 
 
 
  The pattern of use of AAPs and indications for use were reported as percentages along with 
the characteristics of beneficiaries using AAPs off-label and on-label. All statistical analyses were 
conducted using SAS 9.4. 
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4.2 Specific Aim III and IV 
 
Specific Aim IIIA: Compare all-cause RU and costs between Medicare beneficiaries using 
AAPs and those not using AAPs for off-label treatment of mental health conditions. 
 
Specific Aim IIIB: Compare mental health RU and costs between Medicare beneficiaries 
using AAPs and those not using AAPs for off-label treatment of mental health conditions. 
 
Specific Aim IVA: Compare all-cause RU and costs between Medicare beneficiaries using 
AAPs and those not using AAPs for on-label treatment of mental health conditions. 
 
Specific Aim IVB: Compare mental health RU and costs between Medicare beneficiaries using 
AAPs and those not using AAPs for on-label treatment of mental health conditions. 
 
Study design and index period 
For Specific Aims III and IV a retrospective cohort study design was employed using 
Medicare 2008-2010 data. For this section of the study January 1, 2009 – December 31, 2009 was 
defined as the index period enabling the use of 12 months of baseline and 12 months of follow up 
period.  
Eligibility criteria 
From the random sample of one million beneficiaries only those with fee-for-service 
benefit and continuous Medicare enrollment from 2008-2010 across Part A, Part B and Part D 
were included. Fee-for-service beneficiaries were identified using the CNTRCT and HMO_IND 
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variables from the MBSF files. Beneficiaries with a “Stand Alone Prescription Drug Plan” with 
zero months of HMO coverage were considered to be fee-for-service beneficiaries. To have 
continuous enrollment beneficiaries had to have 12 months of Part A, B and D access as denoted 
in the A_MO_CNT, B_MO_CNT and PLNCOVMO variables for each year from January 1, 2008 
to December 31, 2010.  
Population of interest 
  The population of interest was Medicare beneficiaries 18 years and older with a mental 
health condition. Even though Medicare is primarily for patients over 65 years of age, beneficiaries 
who are 18 to 64 years of age were also included since severe mental illness is prevalent among 
Medicare beneficiaries under 65 years who are entitled to Medicare due to a disability. According 
to the Social Security Administration around 37% of all the Medicare disabled beneficiaries have 
severe mental disorders (SSA, 2011). The presence of mental health conditions was identified 
using one of two methods: 
(3) Beneficiaries had to have at least one inpatient or two outpatient mental health claims 
between January 1, 2008 and December 31, 2010. Mental health claims were identified 
using ICD-9-CM codes. These claims were identified from the principal diagnosis, 
admitting diagnosis or any one of the 25 ICD-9-CM variables in the inpatient and 
outpatient files. Mental health claims were identified using ICD-9-CM codes 290.xx – 
319.xx as presented in Table 11. 
 
 
 
 45 
 
Table 11: List of ICD-9-CM codes for mental health conditions from inpatient/outpatient files 
ICD-9-CM Condition ICD-9-CM Condition 
290.xx Dementia 298.xx Non-organic psychoses 
291.xx Alcoholic psychoses 299.xx Psychoses with childhood 
origin 
292.xx Drug psychoses 300.xx Anxiety and neurotic 
disorders 
293.xx Transient organic psychoses 301.xx Personality disorders 
294.xx Other organic psychoses 302.xx Psychosexual disorders 
295.xx Schizophrenia 303.xx –  
305.xx 
Psychoactive substance abuse 
disorders 
296.0, 
296.1, 
296.4-296.9 
Bipolar disorder 306.xx –  
310.xx 
Other mental disorders 
296.2, 
296.3, 311.xx 
Depression 312.xx – 
316.xx 
Other child and adolescent 
origin mental disorders 
297.xx Paranoid states 317.xx – 
319.xx 
Mental Retardation 
 
(ii) Beneficiaries who were flagged as having specific mental health conditions in the 
MBSF Other Chronic Conditions file were also included in the study sample. Medicare uses this 
file to flag beneficiaries who have had at least one inpatient or two outpatient claims for a particular 
condition since the beneficiary enrolled in Medicare. The conditions identified from this file are 
 46 
 
presented in Table 12. The variables in the Other Chronic Conditions file were reassigned to 
different categories of mental health conditions to match the categories described in Table 11. 
Table 12: List of mental health conditions identified from Other Chronic Conditions File 
Variable (As denoted in Medicare) Condition (Reassigned variable names) 
Depression; Depressive disorders Depression 
Alzheimer’s disease Dementia 
Anxiety disorders Neurotic disorders 
Autism spectrum disorders Psychoses with childhood origin 
Bipolar disorder Bipolar disorder 
ADHD, conduct disorders; Learning 
disabilities; Other developmental delays 
Other child and adolescent origin mental 
disorders 
Intellectual disabilities  Mental retardation 
Personality disorders Personality disorders 
Post-traumatic stress disorder Other mental disorders 
Schizophrenia; Schizophrenia and other 
psychotic disorders 
Schizophrenia 
 
Study groups 
The population of interest was then divided into two groups for each Specific Aim. 
Beneficiaries who had a diagnosis of schizophrenia and/or bipolar disorder were categorized as 
the on-label cohort. Beneficiaries who did not have claims for schizophrenia and/or bipolar 
disorder were categorized as the off-label cohort. The off-label cohort was used in the analysis of 
Specific Aim II and the on-label cohort for Specific Aim III.  
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Exposure variable 
The exposure of interest for Specific Aims III and IV was AAPs use during the index 
period. Beneficiaries were considered to be AAPs users if they had at least two claims (>1 day and 
< 60 days apart) for the same antipsychotic agent between January 1, 2009 and December 31, 
2009. The AAPs of interest were aripiprazole (Abilify), olanzapine (Zyprexa), quetiapine 
(Seroquel), risperidone (Risperdal) and ziprasidone (Geodon) and were identified using their 
generic names. The off-label cohort and the on-label cohort were further divided based on their 
AAPs use. The groups identified were: 
Specific Aim 2: Off-label AAPs user and Off-label AAPs non-user 
Specific Aim 3: On-label AAPs user and On-label AAPs non-user 
Exclusion criteria 
Beneficiaries who met the following criteria were excluded from the study. 
1) Beneficiaries who had claims for both an off-label and on-label mental health condition 
were excluded from the study analysis in order to create two mutually exclusive groups. These 
beneficiaries were excluded since there was no conclusive evidence to identify whether or not the 
AAPs were being used to treat on-label conditions.  
2) Beneficiaries with prescription claims for asenapine (Saphris), lurasidone (Latuda) and 
iloperidone (Fanapt) were excluded from the study since these agents received FDA approval 
during and not at the beginning of the index period. Similarly beneficiaries with claims for 
olanzapine/fluoxetine (Symbyax) and 47aliperidone (Invega) were excluded from the study since 
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these agents received approvals for only one of the two FDA approved conditions (schizophrenia 
or bipolar disorder).  
3) Among beneficiaries identified as AAPs non-users, those with prescription claims for 
AAPs of interest in 2008 were excluded to ensure that the non-users were truly not using AAPs 
during the study period.  
After the exclusions were applied to the patient population, the final groups were identified for 
propensity score matching (Figure 2).  
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Figure 2: Flowchart of inclusions and exclusions from original sample 
  
Fee-for-service beneficiaries (≥18 years) with continuous enrollment in Part A, B, and D with 
mental health conditions  
Exclude beneficiaries with both on-label and off-label mental health conditions 
Off-label cohort On-label cohort 
Off-label AAPs Users Off-label AAPs  
Non-Users 
On-label AAPs Users 
 
On-label AAPs  
Non-Users 
Exclude beneficiaries with claims for newer AAPs 
Exclude beneficiaries with claims for AAPs in 2008 among Non-Users 
Specific Aim 2: 
Off-label Users 
Specific Aim 2: 
Off-label Non-Users 
Specific Aim 3:  
On-label Users 
Specific Aim 3: 
On-label Non-Users 
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4.3 Specific Aim V 
 
Specific Aim V: Evaluate differences in RU and associated costs in Medicare 
beneficiaries using AAPs and those not using AAPs to treat specific mental health 
conditions. 
 
After the eligible population of interest was  identified as described for Specific Aims 3 and 4 the 
study groups for Specific Aim 5 were identified.  
Study groups:  
The population of interest that met the eligibility criteria was further divided into mutually 
exclusive groups based on the presence of certain mental health diagnoses. These disease states 
were identified using ICD-9-CM codes: schizophrenia (ICD-9-CM: 295.xx), bipolar disorder 
(ICD-9-CM: 296.0, 296.1, 296.4 - 296.9), depression (ICD-9-CM: 296.2, 296.3, 311.xx), dementia 
(ICD-9-CM: 290.xx, 294.00, 294.10, 294.11, 294.20, 294.21, 294.8), post-traumatic stress 
disorder (ICD-9-CM: 309.81) and obsessive compulsive disorder (ICD-9-CM: 300.3). The 
exposure of interest was AAPs use as described earlier and the groups were categorized into AAPs 
users and non-users.  
Matching: To control for observable differences, the groups were matched using 
propensity score matching. For Specific Aim III, the off-label users and non-users were matched, 
for Specific Aim IV the on-label users and non-users were matched, and for Specific Aim V, the 
AAPs users and non-users within each study group were matched. Matching was used to address 
potential selection bias and confounding between the study groups. The propensity score or the 
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probability of having prescription claims for AAPs of interest was estimated using logistic 
regression wherein AAPs use was coded as a dummy outcome variable.  
Covariates: The covariates in the logistic regression model included age, gender, race, end-
stage-renal-disease indicator, disability indicator, number of unique medications, Charlson-
Comorbidity Index (CCI), mental health conditions, and non-mental health inpatient and outpatient 
visits during the pre-index period.  
Age: 
This variable was identified from the MBSF file and was coded as a continuous    variable 
based on the age of the beneficiary at the end of 2008. Age, found to affect RU in patients with 
mental health disorders (Ginsberg et al., 1997, Twomey et al., 2015), was also coded as categories 
“65 years and under” and “Greater than 65 years” for descriptive purposes.  
Gender:  
This variable was identified from the MBSF file and was coded as a dummy variable. Men 
and women had different comorbid mental health condition profiles (Sajatovis et al., 1997, Dagher 
et al., 2015, Twomey et al., 2015) therefore the variable was retained in the model. For example, 
the study by Twomey et al. reported that adult female patients with mental disorders were 
associated with increased health service utilization.  
Race:  
This variable was identified from the MBSF file and was collapsed to variables “White”, 
“African American” and “Others”. Disparities in mental health care utilization among the different 
races, especially among non-white ethnicities, were reported in previous studies (Wu et al., 2012, 
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Twomey et al., 2015). In order to control for any disparities, this variable was introduced in the 
propensity model. 
End-Stage-Renal-Disease (ESRD):  
This variable identified from MBSF was coded as a dummy variable. This variable denotes 
if the beneficiary has been diagnosed with ESRD, which could also be the reason they are eligible 
for Medicare even if they are younger than 65 years. ESRD is associated with increased health 
care costs and RU (Khan et al., 2002; Blanchette et al., 2015) and accounted for 7.1% of overall 
Medicare paid claims (USRDS, 2014).  
Disability:  
This variable was identified from the MBSF file and was coded as a dummy variable to 
indicate presence or absence of disability. This was an important variable to include since 
beneficiaries who are eligible for Medicare due to their disability versus their age might have 
different RU compared to Medicare beneficiaries over 65 years of age (Ettner, 1998). 
Unique number of medications:  
This quantitative variable was calculated from the PDE file using prescription claims data. 
Unique medications were identified using the GNN variable which lists the drug in its generic 
name. This is an important variable to control for since increased medication use such as 
antidepressant and typical antipsychotic use has led to increased RU (Sheehan et al., 2012). 
Charlson Comorbidity Index:  
Comorbidity was found to be significantly associated with RU among patients with mental 
disorders (Twomey et al., 2015) and therefore was added to the propensity model. The CCI 
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variable was a continuous variable that assigned scores to each beneficiary based on the presence 
of 17 comorbid conditions. The conditions were identified using inpatient claims, outpatient 
claims, the Chronic Conditions file, and the Other Chronic Conditions CCW files using ICD-9-
CM codes (Table 13). This variable was used in retrospective claims database studies to account 
for beneficiary comorbid condition, disease severity and mortality risk (Charlson et al., 1987). 
Even though several adaptions of this variable had been made, Deyo et al. adapted one based on 
ICD-9-CM codes for administrative data (Deyo et al., 1992) and was used in this study. For each 
beneficiary, corresponding scores were identified for each comorbid condition and the sum of the 
scores was the assigned CCI score. For example, a diabetic (CCI score of 1) patient with AIDS 
(CCI score of 6) would have a total CCI score of seven.  
Mental health conditions:  
The different mental health conditions were included as dummy variables in the regression 
model. The conditions were identified from the inpatient and outpatient claims (Table 11) and 
from the CCW files (Table 12). Mental health comorbidities were reported to be important 
predictors of RU (Twomey et al., 2015; Wu et al., 2012; Kawatkar et al., 2014) and were included 
as dummy variables in the matching regression model.  
Baseline RU:  
The number of outpatient visits and inpatient visits were included as two separate 
quantitative variables based on claims data from 2008. Baseline RU was used as a proxy variable 
for severity of illness (Crivera et al., 2011; He at al., 2015). 
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Table 13: Conditions included in Charlson Comorbidity Index (CCI) 
Medical Condition ICD-9-CM codes Score 
Myocardial infarction  410,412 1 
Congestive heart failure 428 1 
Peripheral vascular disease 441, 443.9, 785.4 1 
Cerebrovascular disease 430-438 1 
Chronic obstructive pulmonary disorder  490-496, 500-505, 506.4 1 
Dementia 290 1 
Paralysis 342, 344.1 1 
Diabetes 250.0-250.3, 250.7 1 
Chronic liver disease and cirrhosis 571.2, 571.4-571.6 1 
Ulcers 531.0-531.7, 532.0-532.7, 533.0-533.7, 
534.0-534.7 
1 
Rheumatoid arthritis 714.81, 725, 710, 710.1, 710.4, 714.0-
714.2 
1 
Diabetes with sequelae 250.4-250.6 2 
Chronic renal failure 582,585, 586, 588, 583.0-583.7 2 
Any malignancy  140-172.9, 174-195.8, 200-208.9 2 
Moderate-severe liver disease 572.2-572.8, 456.0-456.1, 456.20, 
456.21 
3 
AIDS 042-044 6 
Metastatic solid tumor 196-199.1 6 
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After computing propensity scores, users (cases) and non-users (controls) were matched 
using the Greedy 5→1 technique (Parsons, Retrieved June 2016). In this method, cases and 
controls were initially matched based on five digits of the propensity score, then matched on four 
digits if appropriate matches were not found. This continued until one digit matching. This 
technique was chosen since it maximizes the number of matched pairs. 
Propensity score matching is framed on two theoretical assumptions; the conditional 
independence assumption (CIA) and the common support condition (CSC) (Rosenbaum & Rubin, 
1983). The CIA assumes that after the groups are matched and covariates are controlled, the groups 
have similar probability of receiving AAPs treatment. This assumption heavily relies on the 
researcher’s ability to include all variables that are relevant to the decision of receiving treatment. 
This assumption cannot be directly tested and hence it is assumed that all relevant variables are 
included in the model. The CSC assumes that there is sufficient overlap among the characteristics 
of the cases and controls to ensure adequate matching. This assumption was tested in two ways: 
1) Using a visual overlap plot of the propensity scores of the cases and controls. The scores 
were plotted as box-plot and histogram plots and were visually compared to determine if 
appropriate overlap existed. 
  2) By comparing the means of the propensity scores between cases and controls using the   
Kolmogorov-Smirnov non-parametric test to statistically determine if overlap existed.  
Absolute standardized difference was used to assess balance among the covariates between 
cases and controls before and after matching since p-values depend on the type of statistical test 
used and sample size (Sullivan & Feinn, 2012). The categorical variable Race was represented 
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using binary indicator variables. Absolute standardized differences less than 10% indicated 
negligible differences between the groups.  
For continuous variables the absolute standardized difference is 
 
For categorical variables, 
 
where   and   are the means of the variables in the exposed and unexposed cohorts,  and   
denote the variances of the variables and  and  denote the proportion in the groups.  
Index dates: For the AAPs users the date of the first AAPs prescription claim received 
during the index period (January 1, 2009 and December 31, 2009) was assigned as the index date. 
AAPs non-users, since they do not have a claim for AAPs during the index period, were assigned 
the corresponding date as their matched case.  
Outcome measure 
The primary outcome of interest was all-cause RU and associated costs during the 12 
month follow up period after the index date. RU included inpatient visits, hospital outpatient visits 
and prescription claims. The costs associated with these resources and total costs were also 
assessed and reported. The amounts paid by Medicare and other third party payers were obtained 
from the base inpatient and outpatient claims files but the beneficiary share was obtained from the 
Revenue Center files which were cross-linked using unique Claim IDs. A third party payer was 
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any entity, such as private health plans that paid for a share of the costs along with Medicare and 
the beneficiary. The individual cost components were computed as follows: 
𝑀𝑒𝑑𝑖𝑐𝑎𝑟𝑒 𝑠ℎ𝑎𝑟𝑒 = 𝐴𝑚𝑜𝑢𝑛𝑡 𝑝𝑎𝑖𝑑 𝑏𝑦 𝑀𝑒𝑑𝑖𝑐𝑎𝑟𝑒 + (𝐷𝑖𝑒𝑚 𝑎𝑚𝑜𝑢𝑛𝑡 𝑝𝑎𝑖𝑑 ∗ 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑐𝑙𝑎𝑖𝑚) 
𝐵𝑒𝑛𝑓𝑖𝑐𝑖𝑎𝑟𝑦 𝑠ℎ𝑎𝑟𝑒 = 𝐷𝑒𝑑𝑢𝑐𝑡𝑖𝑏𝑙𝑒 + 𝐶𝑜𝑖𝑛𝑠𝑢𝑟𝑎𝑛𝑐𝑒 + 𝐵𝑙𝑜𝑜𝑑 𝑑𝑒𝑑𝑢𝑐𝑡𝑖𝑏𝑙𝑒 
𝑇𝑜𝑡𝑎𝑙 = 𝑀𝑒𝑑𝑖𝑐𝑎𝑟𝑒 𝑠ℎ𝑎𝑟𝑒 + 𝑇ℎ𝑖𝑟𝑑 𝑝𝑎𝑟𝑡𝑦 𝑝𝑎𝑦𝑚𝑒𝑛𝑡 + 𝐵𝑒𝑛𝑓𝑖𝑐𝑖𝑎𝑟𝑦 𝑠ℎ𝑎𝑟𝑒 
 All costs associated with emergency department visits were captured in either the inpatient or 
outpatient billing depending on whether the patient was admitted (inpatient) or discharged 
(outpatient) after their emergency visit. All positive costs were inflated to 2015 U.S. dollars using 
the Medical component of Consumer Price Index (CPI) obtained from the Bureau of Labor 
Statistics (BLS, Retrieved August 2016) (Table 14). 
Table 14: Consumer Price Index (CPI) 2009-2015 
 2009 2010 2015 
Prescription 391 407.8 483 
Medical Care Services 397 411 483.6 
 
The secondary outcome was mental health RU and costs. Mental health inpatient and 
outpatient visits were identified using ICD-9-CM codes 290.xx – 319.xx in the principal diagnosis, 
admitting diagnosis or the first three diagnosis variables in the inpatient and outpatient files. 
Mental health medication costs included prescriptions for antipsychotics, antidepressants, 
anxiolytics, and mood stabilizers.  
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Statistical analyses 
Descriptive analysis of the study population was done before matching. Continuous 
variables were described using means and standard deviations and categorical variables were 
described using counts and percentages. The sample after matching was described similarly and 
balance between covariates was assessed using absolute standardized differences. 
RU and costs were assessed for 12 months after the index date and compared between users 
and non-users. RU was estimated as mean number of visits and compared using the paired t-test. 
Whenever the normality assumption was violated the Wilcoxon sign-rank test was used. Normality 
was assessed using Q-Q plots and Kolmogorov-Smirnov test. RU was also reported as the 
percentage of beneficiaries who utilized the services. Conditional logistic regression analysis was 
used to assess the risk of utilizing inpatient or outpatient services among users and non-users. For 
this analyses, separate regression models were created for inpatient and outpatient visits and the 
visit was dichotomized as a dummy variable. 
Costs were estimated as mean inpatient, outpatient, prescription, and total costs. The 
breakdown of these costs based on payers was also reported to include Medicare, beneficiary and 
other primary payers. The difference in the paired costs was assessed using both the mean (paired 
t-test) and the median (Wilcoxon sign-rank test and Sign test) since cost data is not normally 
distributed but is typically right skewed with a long tail. The results of all 3 tests were reported as 
paired t-tests are sensitive to outliers unlike the other two tests but the Wilcoxon does take into 
account the extreme observations unlike the Sign test. SAS v 9.4 (SAS Institute, Cary, NC) was 
used for all analyses and a significance level of α = 0.05 was set a-priori. 
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4.4 Sensitivity Analyses 
 
A sensitivity analyses is recommended anytime there is uncertainty within the data (Briggs, 
1999). It is therefore good practice to examine the changes in the RU and costs patterns when some 
of the assumptions in the study are varied. 
1) AAPs users were defined as those beneficiaries who had claims for AAPs in 2009 which 
included both existing and new users. In the sensitivity analyses all beneficiaries who had AAPs 
claims in 2008 were excluded to estimate the differences in follow up RU and costs for new AAPs 
users and those not using AAPs. 
2) Another assumption in the study was to only include schizophrenia and bipolar disorder 
as FDA approved conditions for aripiprazole even though it has been approved for adjunctive 
treatment of depression. Therefore, there may be aripiprazole users with depression in the off-label 
cohort, thus overestimating costs in that group. The results were tested after excluding aripiprazole 
from the AAPs of interest. 
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Chapter 5: Results 
5.1 Specific Aim II 
 
Specific Aim II: Evaluate the prevalence of off-label and on-label use of AAPs and 
describe patient characteristics in a Medicare population. 
Population of interest: In the random sample obtained from CMS for 2008 (N=891,082), 2009 
(N=905,814) and 2010 (N=922,202), a cohort of 813,656 beneficiaries was followed across all 
three years. Within each year the population of interest i.e. AAPs users was identified. The 
beneficiaries using AAPs are described in Table 15 and the distribution of use among the AAPs is 
shown in Figure 3. The prevalence of AAPs use has remained constant across the years with 
majority of beneficiaries using quetiapine and risperidone.  
Table 15: Overall annual trend of atypical antipsychotic users from 2008-2010 
 2008 2009 2010 
Total Beneficiaries 891,082 905,814 922,202 
AAPs Users 28,537 (3.20%) 29,280 (3.23%) 29,831 (3.23%) 
Age   
   -Mean (years) 
   -Less than 65 years 
   -65 years and older 
 
64.04+19.40 (18-106) 
14,065 (49.29%) 
14,472 (50.71%) 
 
63.50+19.17 (20-106) 
14,913 (50.93%) 
14,367 (49.07%) 
 
63.24+19.04 (20-107) 
15,442 (51.76%) 
14,389 (48.24%) 
Sex  
   -Male 
 
10,858 (38.05%) 
 
11,296 (38.58%) 
 
11,646 (39.04%) 
Race 
   -White 
   -African American  
   -Others 
 
22,560 (79.06%) 
4,001 (14.02%) 
1,976 (6.92%) 
 
23,122 (78.97%) 
4,068 (13.89%) 
2,090 (7.14%) 
 
23,458 (78.64%) 
4,158 (13.94%) 
2,215 (7.43%) 
ESRD 199 (0.70%) 222 (0.76%) 204 (0.68%) 
Disability 14,255 (49.95%) 15,155 (51.76%) 15,756 (52.82%) 
Abbreviation used: ESRD, End-Stage Renal Disease 
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Figure 3: Pattern of atypical antipsychotic use from 2008-2010 
 
Off-label use: The prevalence of off-label and on-label use of AAPs and the characteristics 
of the beneficiaries are described in Table 16. Approximately 37% of total AAPs use was in the 
absence of an FDA approved indication and this was consistent across the three years. More than 
60% of the beneficiaries receiving AAPs for off-label treatment of mental health conditions were 
older than 65 years and majority were white females without ESRD or a disability. . Among AAPs 
users older than 65 years, 49% were off-label users. Majority of these beneficiaries had indications 
for depression, neurotic disorders or other organic psychoses (Figure 4). In 2008, 53.8% of the off-
label AAPs users had depression and approximately 31% had dementia and other related organic 
psychosis. By 2010, these numbers had decreased to 48.6% depression and 24.8% dementia and 
related psychosis.  
2008 2009 2010
15.31 17.40 17.33
21.47 19.76 18.59
43.13 43.75 43.95
34.60 33.01 33.53
7.63 7.48 7.40
PATTERN OF AAPS USE FROM 
2008-2010 (%)
Aripirazole Olanzapine Quetiapine Risperidone Ziprasidone
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On-label use: The prevalence of beneficiaries using AAPs in the presence of an FDA 
approved indications remained 63% across the three years (Table 16). Of these on-label AAPs 
users; 82.46%, 80.47% and 78.33% had diagnosis for schizophrenia and 55.47%, 56.48% and 
56.91% had diagnosis for bipolar disorder in 2008, 2009 and 2010 respectively 
Table 16: Patterns of off-label and on-label use of AAPs from 2008-2010 
 2008 
(N=28,537) 
2009 
(N=29,280) 
2010 
(N=29,831) 
Off-label Users 10,476 (36.71%) 10,679 (36.47%) 10,876 (36.46%) 
Age   
   -Mean (years) 
   -Less than 65 years 
   -65 years and older 
 
70.69+18.71 (18-104) 
3,409 (32.54%) 
7,067 (67.46%) 
 
69.90+18.66 (20-106) 
3,684 (34.50%) 
6,995 (65.50%) 
 
69.54+18.58 (20-107) 
3,867 (35.56%) 
7,009 (64.44%) 
Sex  
   -Male 
 
3,397 (32.43%) 
 
3,546 (33.21%) 
 
3,678 (33.82%) 
Race 
   -White 
   -African American  
   -Others 
 
8,575 (81.85%) 
1,131 (10.80%) 
770 (7.35%) 
 
8,714 (81.60%) 
1,125 (10.53%) 
840 (7.87%) 
 
8.846 (81.34%) 
1,116 (10.26%) 
914 (8.40%) 
ESRD 79 (0.75%) 90 (0.84%) 73 (0.67%) 
Disability 3,448 (32.91%) 3,735 (34.98%) 3,954 (36.36%) 
    
On-label Users 18,061 (63.29%) 18,601 (63.53%) 18,955 (63.54%) 
Age   
   -Mean (years) 
   -Less than 65 years 
   -65 years and older 
 
60.18+18.74 (20-106) 
10,656 (59.00%) 
7,405 (41.00%) 
 
59.83+18.48 (20-105) 
11,229 (60.37%) 
7,372 (39.63%) 
 
59.63+18.34 (20-106) 
11,575 (61.07%) 
7,380 (38.93%) 
Sex  
   -Male 
 
7,461 (41.31%) 
 
7,750 (41.66%) 
 
7,968 (42.04%) 
Race 
   -White 
   -African American  
   -Others 
 
13,985 (77.43%) 
2,870 (15.89%) 
1,206 (6.68%) 
 
14,408 (77.46%) 
2,943 (15.82%) 
1,250 (6.72%) 
 
14,612 (77.09%) 
3,042 (16.05%) 
1,301 (6.86%) 
ESRD 120 (0.66%) 132 (0.71%) 131 (0.69%) 
Disability 10,807 (59.84%) 11,420 (61.39%) 11,802 (62.26%) 
Abbreviation used: ESRD, End-Stage Renal Disease 
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*Percent’s do not add to 100 since some patients had more than one condition 
Figure 4: Distribution of mental health conditions among off-label AAPs users  
 
In the following section the population of interest and study groups identified for Specific Aims 
III, IV and V are described. This is followed by the description of the outcomes for the individual 
aims. 
 
Population of interest: From the random sample of one million beneficiaries, 238,127 
beneficiaries met the eligibility criteria i.e., fee-for-service beneficiaries with three years of 
continuous enrollment in Medicare Part A, B and D. Of the beneficiaries who met the eligibility 
criteria N=108,937 were identified to be the population of interest (Figure 5). These beneficiaries 
were greater than 18 years and had a diagnosis for a mental health condition as identified from the 
inpatient, outpatient and other chronic conditions files. The population of interest was divided into 
two mutually exclusive groups; the off-label cohort (N=78,708) comprised beneficiaries with any 
mental health conditions except bipolar disorder or schizophrenia and on-label cohort (N=3,846) 
7.25
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comprised beneficiaries with only schizophrenia and/or bipolar disorder. A subset of 26,383 
beneficiaries was excluded since they had a diagnosis for both an off-label and on-label condition.  
AAPs users: The off-label and on-label cohort were categorized into AAPs users and non-
users based on AAPs claims. The Part D claims file was used to identify 16,056 AAPs users with 
a mental health condition in 2009.  Quetiapine was the most frequently dispensed AAPs while 
ziprasidone was the least frequent (Figure 6). Of these beneficiaries, 21.6% were using AAPs in 
the absence of a FDA approved indication (Figure 7). The off-label and on-label cohorts were 
further categorized based on their AAPs use. In the off-label cohort there were 3,468 (4.41%) 
beneficiaries who were AAPs users and 1,242 (32.29%) beneficiaries were AAPs users in the on-
label cohort (Figure 5). After beneficiaries who had prescription claims for newer AAPs (N=107) 
and who had prescription claims for AAPs the previous year (N=772) were excluded, the final 
study groups for each Specific Aim were shown in Figure 5.  
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Figure 5: Flow of beneficiaries to identify study groups for Specific Aims III and IV 
 
 
 
Fee-for-service beneficiaries (≥18 years) with continuous enrollment in Part A, B, and D with 
mental health conditions (N=108,937) 
Exclude beneficiaries with both on-label and off-label mental health conditions (N=26,383) 
Off-label cohort (N=78,708) On-label cohort (N=3,846) 
Off-label AAPs Users 
(N=3,468) 
Off-label AAPs  
Non-Users (N=75,240) 
On-label AAPs Users 
(N=1,242) 
On-label AAPs  
Non-Users (N=2,604) 
Exclude beneficiaries with claims for newer AAPs (N=107) 
Exclude beneficiaries with claims for AAPs in 2008 among Non-Users (N=772) 
Specific Aim 2: 
Off-label Users 
(N=3,457) 
Specific Aim 2: 
Off-label Non-Users 
(N=74,557) 
Specific Aim 3:  
On-label Users 
(N=1,219) 
Specific Aim 3: 
On-label Non-Users 
(N=2,442) 
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Figure 6: Pattern of AAPs use among mental health beneficiaries in 2009 (%) 
 
 
Figure 7: Prevalence of off-label AAPs use among AAPs users in 2009 
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5.2 Specific Aim III 
 
Specific Aim IIIA: Compare all-cause RU and costs between Medicare beneficiaries using 
AAPs and those not using AAPs for off-label treatment of mental health conditions. 
 
Pre-match study groups: For this aim, the study groups identified were the off-label AAPs 
user cohort (N=3,457) and the off-label AAPs non-user cohort (N=74,557) before propensity score 
matching. Absolute standardized differences were computed to check for differences between the 
groups (Table 17). The groups differed in their mean age, number of medications used in the 
previous year, frequency of beneficiaries with disability, and prevalence of certain mental health 
conditions such as depression and psychoactive substance use.  Users were slightly younger than 
non-users; majority of the users were less than 65 years whereas majority of the non-users were 
65 to 84 years. The AAPs users took more medications compared to non-users but did not differ 
from non-users in their inpatient and outpatient utilization rates. 
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Table 17: Baseline characteristics of off-label cohort pre-matching 
 
Variable AAPs User 
(N=3,457) 
AAPs Non-User 
(N=74,557) 
p-valuea Standardized 
Difference (%) 
Demographic 
Age (years) 66.19 + 18.44 69.65 + 14.89 <0.0001 20.63 
   <65 1494 (43.22%) 20423 (27.39%)   
   65-84 1306 (37.78%) 43881 (58.86%)   
   >=85 657 (19.00%) 10253 (13.75%)   
Male 1138 (32.92%) 21740 (29.16%) <0.0001 8.13 
Race     
   White  2874 (83.14%) 62308 (83.57%) 0.4997 1.17 
   Black  352 (10.18%) 7582 (10.17%) 0.9805 0.04 
   Others 231 (6.68%) 4667 (6.26%) 0.3168 1.71 
Disease Burden 
CCI 0.90 + 1.47 1.01 + 1.60 <0.0001 7.25 
No. of medications 12.73 + 7.51 10.53 + 6.64 <0.0001 31.04 
ESRD 16 (0.46%) 947 (1.27%) <0.0001 8.72 
Disability 1517 (43.88%) 20920 (28.06%) <0.0001 33.43 
Mental Health Disorders 
Depression 2528 (73.13%) 45320 (60.79%) <0.0001 26.47 
Anxiety and Neurotic d/o 1818 (52.59%) 36749 (49.29%) <0.0001 6.60 
Psychoactive Substance Use 376 (10.88%) 12231 (16.40%) <0.0001 16.16 
Mental Retardation 589 (17.04%) 4601 (6.17%) <0.0001 34.43 
Other Organic Psychoses 935 (27.05%) 7177 (9.63%) <0.0001 46.20 
Other Mental Disorders 277 (8.01%) 2887 (3.87%) <0.0001 17.58 
Personality  201 (5.81%) 915 (1.23%) <0.0001 25.08 
Dementia 294 (8.50%) 1812 (2.43%) <0.0001 26.96 
Child and Adolescent d/o 161 (4.66%) 807 (1.08%) <0.0001 21.53 
Child Organic Psychoses 161 (4.66%) 279 (0.37%) <0.0001 27.61 
Transient Organic Psychoses 95 (2.75%) 1144 (1.53%) <0.0001 8.39 
Psychosexual d/o 6 (0.17%) 132 (0.18%) 0.9620 0.08 
Drug Psychoses 25 (0.72%) 627 (0.84%) 0.4570 1.34 
Alcoholic Psychoses 22 (0.64%) 409 (0.55%) 0.4959 1.14 
Non-Organic Psychoses 2 (0.06%) 40 (0.05%) 0.9170 0.18 
Paranoiab 0 1 (0%) 0.8295 0.52 
Resource Utilization 
Inpatient 0.36 + 0.98 0.39 + 0.93 0.0270 3.93 
Outpatient 5.02 + 6.93 5.48 + 5.43 <0.0001 6.46 
aPooled or Satterthwaite p-value for t-test based on test of equal variances 
bNot included in the propensity score model since there are zero cases 
Abbreviation used: d/o; disorder 
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Propensity scores for off-label users and non-users were computed using logistic 
regression. Figures 8a and 9a illustrate the distribution of the propensity scores in the two groups 
before matching using the box-plot and histogram techniques and show overlapping distributions 
indicating that the common support assumption holds true. The mean scores are significantly 
different among users and non-users as seen by the Kolmogorov-Smirnov two sample test 
(p<0.0001) and hence matching between the groups was done to remove baseline differences.  
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1: AAPs Users; 0: Non-Users 
 
 
Figure 8a: Distribution of propensity scores before matching 
 
 
1: AAPs Users; 0: Non-Users 
 
Figure 8b: Distribution of propensity scores after matching  
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1: AAPs Users; 0: Non-Users 
 
Figure 9a: Distribution of propensity scores before matching – Boxplot 
 
1: AAPs Users; 0: Non-Users 
 
Figure 9b: Distribution of propensity scores after matching – Boxplot 
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Post-match study groups: After matching, no difference was found among the means of 
the propensity scores between the cohorts (p=1.0000). Figures 8b and 9b also visually illustrate 
that the distribution of scores were very similar across the two groups after matching. The number 
of beneficiaries in the AAPs user and non-user cohort before and after matching is reported in 
Table 18.  
 
Table 18. Pre and post-match cohort counts 
 
 Frequency Percent Cumulative 
Frequency 
Cumulative 
percent 
Pre     
Control 74557 95.57 74557 95.57 
Case 3457 4.43 78014 100.00 
Post     
Control 3438 50.00 3438 50.00 
Case 3438 50.00 6876 100.00 
 
To assess if the propensity score matching process balanced the covariates across the two 
groups, absolute standardized differences were calculated (Table 19). All standardized differences 
are less than 10%; hence good matches with balanced observed covariates were obtained. The 
groups had a mean age of 66 years, comprised mostly white females an average of 13 unique 
medications. In addition, majority of beneficiaries had a diagnosis for depression or neurotic 
disorders. 
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Table 19: Baseline characteristics of off-label cohort post-matching 
 
Variable AAPs User 
(N=3,438) 
AAPs Non-User 
(N=3,438) 
Standardized 
Difference (%) 
Demographic 
Age (years) 66.29+18.42 (20-101) 66.01+17.44 (21-104) 1.53 
   <65 1477 (42.96%) 1516 (44.10%)  
   65-84 1304 (37.93%) 1368 (39.79%)  
   >=85 657 (19.11%) 554 (16.11%)  
Male 1130 (32.87%) 1123 (32.66%) 0.43 
Race    
   White  2858 (83.13%) 2794 (81.27%) 4.87 
   Black  350 (10.18%) 380 (11.05%) 2.83 
   Others 230 (6.69%) 264 (7.68%) 3.83 
Disease Burden 
CCI 0.90+1.48  0.98+1.51  4.88 
No. of medications 12.70+7.39 13.13+8.04 5.54 
ESRD 16 (0.47%) 20 (0.58%) 1.61 
Disability 1500 (43.63%) 1549 (45.06%) 2.87 
Mental Health Disorders 
Depression 2516 (73.18%) 2561 (74.49%) 2.98 
Neurotic 1804 (52.47%) 1771 (51.51%) 1.92 
Psychoactive Substance 376 (10.94%) 375 (10.91%) 0.09 
Mental Retardation 572 (16.64%) 548 (15.94%) 1.89 
Other Organic Psychoses 925 (26.91%) 974 (28.33%) 3.19 
Other Mental Disorders 273 (7.94%) 274 (7.97%) 0.11 
Personality  199 (5.79%) 187 (5.44%) 1.52 
Dementia 290 (8.44%) 269 (7.82%) 2.23 
Child and Adolescent  150 (4.36%) 136 (3.96%) 2.04 
Child Organic Psychoses 151 (4.39%) 99 (2.88%) 8.09 
Transient Organic Psychoses 92 (2.68%) 94 (2.73%) 0.36 
Drug Psychoses 25 (0.73%) 22 (0.64%) 1.06 
Alcoholic Psychoses 22 (0.64%) 18 (0.52%) 1.53 
Psychosexual 6 (0.17%) 6 (0.17%) 0 
Non-Organic Psychoses 2 (0.06%) 0 3.41 
Resource Utilization 
Inpatient 0.36+0.98 0.38+0.88 2.71 
Outpatient 5.02+6.94 5.34+6.67 4.69 
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Costs: Table 20 presents direct all-cause health care costs for beneficiaries by AAPs use to 
treat off-label mental health conditions during the follow-up period. Costs were broken down 
based on payers; Medicare costs, out-of-pocket costs by the beneficiary and other payers such as 
a private insurance. Medicare followed by beneficiaries paying out-of-pocket paid the largest share 
of costs. Beneficiaries had to pay the highest share out-of-pocket for prescriptions and these costs 
were higher among the AAPs users as compared to the non-users. Among the total health care 
costs, the major cost component among non-users was inpatient (IP) cost but among the AAPs 
users it was prescription cost (RX) (Figure 10). Outpatient (OP) costs remained similar in both 
cohorts. 
 
Figure 10: Breakdown of direct health care costs through the follow-up period 
 
Out of the 6,876 beneficiaries after matching only 29 beneficiaries (0.4%) had zero total 
costs and therefore no measures were undertaken to account for a high number of zero costs in the 
analyses. Univariate analyses of total costs showed a right skew distribution with a maximum cost 
of $455,000 (Figure 11) and hence both total mean (paired t-test) and median (Wilcoxon Sign-
Rank test) costs were reported in Table 20. Of the total beneficiaries, 69 had costs greater than 
 75 
 
$92,500 (99% quantile).  Due to the presence of some extreme observations the Sign test was also 
reported in Table 21. The Sign test assessed differences in median cost in the absence of extreme 
observations. Even though there were no differences in the total mean costs between AAPs users 
and non-users (p=0.6112), AAPs non-users had significantly higher inpatient costs of $6,945 per 
person versus the $4,841 per person among users (p <0.0001). On the other hand, prescription 
costs were significantly higher among the users by approximately $1,700 which would also include 
the cost of AAPs. Since the cost data is not normally distributed and may be sensitive to extreme 
observations, medians were also reported. Median outpatient costs among non-users were 
significantly higher than among users even though no differences were found between mean 
outpatient costs.  
 
 
 
Figure 11: Distribution of total costs in off-label cohort 
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Table 20: Direct all-cause health care costs by payer 
 
Variable 
 
Mean 
($) 
Lower 
95% CI 
Upper 
95% CI 
Median  
($) 
Minimum 
($) 
Maximum 
($) 
AAPs Non-Users       
Outpatient        
   Medicare 2,117 1,953 2,282 683 0 89,071 
   Beneficiary 588 546 629 206 0 17,595 
   Other payers 15 3 27 0 0 12,744 
Inpatient        
   Medicare 6,295 5,678 6,912 0 0 358,363 
   Beneficiary 539 494 583 0 0 51,147 
   Other payers 111 -80 303 0 0 335,446 
Prescription        
   Medicare 3,256 3,059 3,454 1,915 0 125,953 
   Beneficiary 880 854 906 687 0 5,548 
AAPs Users       
Outpatient             
   Medicare 2,056 1,893 2,219 620 0 61,586 
   Beneficiary 574 531 617 182 0 16,608 
   Other payers 14 2 26 0 0 18,796 
Inpatient        
   Medicare 4,412 3,954 4,869 0 0 218,776 
   Beneficiary 395 358 432 0 0 44,667 
   Other payers 34 4 65 0 0 38,259 
Prescription        
   Medicare 4,855 4,695 5,015 3,739 25 86,396 
   Beneficiary 1,066 1,040 1,092 896 12 6,378 
Abbreviation used: CI, Confidence interval 
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Table 21: Mean all-cause health care costs for AAPs users and non-users 
Variable Non-Users Users 
p-value 
Mean 
($) 
Median 
($) 
SD Mean 
($) 
Median  
($) 
SD Paired 
t-test 
Sign WSR 
Outpatient  2,720 897 6,129 2,644 837 6,159 0.6112 0.0013 0.0181 
Inpatient  6,945 0 20,238 4,841 0 14,389 <0.0001 <0.0001 <0.0001 
Prescription  4,137 2,630 6,442 5,921 4,742 5,310 <0.0001 <0.0001 <0.0001 
Total  13,801 6,389 23,704 13,407 7,979 18,130 0.4373 <0.0001 0.0002 
 - Medicare 11,669 4,788 21,335 11,323 6,283 16,614 0.4536 <0.0001 <0.0001 
Abbreviation used: SD, Standard Deviation; WSR, Wilcoxon Sign-Rank  
 
Resource Utilization: The descriptive statistics and patterns of RU by beneficiaries using 
and those not using AAPs off-label to treat their mental health conditions are reported in Table 22.  
In the 12 month follow-up period both users and non-users had an average of six outpatient visits 
per year and 13 medications per year with no significant differences among the cohorts (Table 23) 
except for the number of medication claims. On the other hand beneficiaries who used AAPs for 
off-label treatment had significantly lower number of inpatient visits (p <0.0001) during the 
follow-up period. The maximum number of times an AAPs user used an inpatient service was 10 
times a year in comparison to the 14 visits by a non-user.  
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Table 22: Annual health care RU among off-label AAPs users and non-users 
Variable Mean Lower 95% CI Upper 95% CI Min Max 
AAPs Non-Users           
Outpatient visits 6.39 6.12 6.66 0 103 
Inpatient visits 0.58 0.54 0.61 0 14 
Medication claims 67.50 65.85 69.14 0 428 
Unique medications 13.08 12.82 13.34 0 51 
AAPs Users       
Outpatient visits 6.41 6.11 6.71 0 128 
Inpatient visits 0.41 0.38 0.45 0 10 
Medication claims 84.78 83.10 86.46 2 596 
Unique medications 13.22 12.97 13.46 1 54 
Abbreviation used: CI, Confidence interval; Min, Minimum; Max, Maximum 
 
Table 23: Differences in RU between off-label AAPs users and non-users 
Variable Difference 
(Non-Users-Users) 
SD Lower  
95% CI 
Upper 
 95% CI 
p-value 
Outpatient visits -0.02 12.06 -0.42 0.38 0.2106 
Inpatient visits 0.16 1.47 0.11 0.21 <0.0001 
Medication claims -17.28 67.74 -19.55 -15.02 <0.0001 
Unique medications -0.14 10.46 -0.49 0.21 0.4445 
Abbreviation used: CI, Confidence interval; SD, Standard Deviation 
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Logistic regression analyses reported in Table 24 showed that AAPs users had 34% lower 
odds than non-users  to have an inpatient visit (p <0.0001). Among the AAPs users only 24% had 
at least one inpatient visit while at least 32% had an inpatient visit among the non-users. More than 
80% of both users and non-users had at least one outpatient visit during the follow-up period. 
 
Table 24: Odds ratios of RU between off-label AAPs users and non-users 
Variable Non-User 
 (%) 
User 
 (%) 
OR 
Non-User=Ref 
Lower 
95% CI 
Upper 
95% CI 
p-value 
Outpatient visits 2869 (83.4) 2816 (81.91) 0.896 0.79 1.017 0.0891 
Inpatient visits 1101 (32.02) 831 (24.17) 0.661 0.592 0.738 <0.0001 
Medication use 3388 (98.55) 3438 (100.00) *       
Abbreviation used: CI, Confidence interval; OR, Odds Ratio 
* Regression not done since 100% medication use in user cohort 
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Specific Aim IIIB: Compare mental health RU and costs between Medicare beneficiaries 
using AAPs and those not using AAPs for off-label treatment of mental health conditions. 
 
Costs: Beneficiaries in the AAPs user cohort had higher total mental health costs during 
the follow-up period (Table 25). The mean total costs among AAPs users were $3,665 versus 
$1,297 among the non-users (p <0.0001). Prescription costs and outpatient costs were higher 
among the AAPs users as compared to non-users but no differences were seen among inpatient 
costs. Majority of the costs were attributed to prescription costs which were $2,349 per AAPs 
user and $282 per non-user (p<0.0001). Of the five AAPs of interest, risperidone contributed 
least to the prescription costs ($397 per beneficiary) while quetiapine contributed the most 
($3562 per beneficiary) followed by aripiprazole and olanzapine ($2,769 per beneficiary and 
$2,478 per beneficiary respectively). 
Table 25: Mean mental health costs among AAPs users and non-users 
Variable Non-Users Users Difference ($) p-value 
Mean ($) SD Mean ($) SD 
Outpatient  297 1,917 461 2,378 -165 0.0017 
Inpatient 719 3,596 854 4,019 -135 0.1314 
Prescription 282 542 2,349 2,311 -2,068 <0.0001 
Total 1,297 4,278 3,665 5,211 -2,368 <0.0001 
 - Medicare 1,086 3,838 3,162 4,655 -2,076 <0.0001 
Abbreviation used: SD, Standard Deviation 
Resource Utilization: The mean number of outpatient and inpatient visits and medications 
used are described in Table 26. In the 12 month follow-up period users had an average of more 
than one outpatient visit per year. About 30% of AAPs users had at least one outpatient visit during 
the year versus only 23% of non-users (Table 27). Regression analyses showed that the odds of 
having an outpatient visit among AAPs users was significantly higher as compared to non-users 
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(OR = 1.55, p <0.0001). No difference was found in the mean number of mental health inpatient 
visits between the groups (Table 26) and approximately 7% of beneficiaries had at least one 
inpatient visit over the period of one year (Table 27). AAPs users also had significantly higher 
number of medications and medication claims compared to non-users (p<0.0001).  
 Table 26: Mean annual mental health RU 
Variable Non-Users Users p-value 
Mean  Lower  
95% CI 
Upper  
95% CI 
Mean  Lower  
95% CI 
Upper  
95% CI 
Outpatient visits 0.61 0.54 0.67 1.06 0.94 1.17 <0.0001 
Inpatient visits 0.08 0.07 0.09 0.09 0.08 0.11 0.0769 
Medication claims 6.97 6.68 7.25 21.89 21.47 22.31 <0.0001 
Unique medications 1.05 1.01 1.08 2.48 2.44 2.52 <0.0001 
Abbreviation used: CI, Confidence interval 
 
Table 27: Odds ratios of mental health RU  
Variable Non-User 
(%) 
User 
 (%) 
OR 
Non-User=Ref 
Lower 
95% CI 
Upper 
95% CI 
p-value 
Outpatient visits 775 (22.54) 1059 (30.80) 1.553 1.39 1.735 <0.0001 
Inpatient visits 226 (6.57) 257 (7.48) 1.156 0.956 1.397 0.1348 
Medication use 2202 (64.05) 3438 (100.00) *       
Abbreviation used: CI, Confidence interval; OR, Odds Ratio 
* Regression not done since 100% medication use in user cohort 
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5.3 Specific Aim IV 
 
Specific Aim IV A: To compare all-cause resource utilization and costs between Medicare 
beneficiaries using AAPs and those not using AAPs for on-label treatment of mental health 
conditions. 
Pre-match study groups: For this aim, the study groups identified before matching were 
on-label AAPs user cohort (N=1,219) and on-label AAPs non-user cohort (N=2,442). The 
characteristics of these beneficiaries are described in Table 28 and the cohorts were different across 
multiple covariates. The typical AAPs user was a younger white male with fewer comorbid 
conditions but higher chances of disability and having a diagnosis for schizophrenia or bipolar 
disorder as compared to the typical non-user. The cohorts also differed in their RU with AAPs 
users having lower numbers of inpatient and outpatient visits the prior year.  
After the propensity scores were computed using logistic regression model, the scores were 
plotted and the overlapping graphs indicated that the common support assumption held true 
(Figures 10a and 11a). The Kolmogorov-Smirnov two sample test showed that the propensity 
scores were significantly different among the users and non-users (p<0.0001).  
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Table 28: Baseline characteristics of on-label cohort pre-matching 
 
Variable AAPs User 
(N=1,219) 
AAPs Non-User 
(N=2,442) 
p-valuea Standardized 
Difference (%) 
Demographic 
Age (years) 51.70 +15.70 66.14+17.78 <0.0001 86.07 
Male 763 (62.59%) 1160 (47.50%) <0.0001 30.69 
Race     
   White  833 (68.33%) 1839 (75.31%) <0.0001 15.55 
   Black  269 (22.07%) 428 (17.53%) 0.0010 11.41 
   Others 117 (9.60%) 175 (7.17%) 0.0105 8.78 
Disease Burden 
CCI 0.32+0.91 0.74+1.41 <0.0001 34.90 
No. of medications 7.17+4.96 7.64+5.97 0.0108 8.67 
ESRD 3 (0.25%) 28 (1.15%) 0.00051 10.84 
Disability 960 (78.75%) 1018 (41.69%) <0.0001 81.82 
Mental Health Disorders 
Schizophrenia 1024 (84.00%) 1836 (75.18%) 0.0011 22.01 
Bipolar Disorder 454 (37.24%) 777 (31.82%) <0.0001 11.43 
Resource Utilization 
Inpatient 0.05+0.29 0.23+0.70 <0.0001 32.40 
Outpatient 2.25+4.35 3.87+6.30 <0.0001 29.93 
aPooled or Satterthwaite p-value for t-test based on test of equal variances 
 
Post-match study groups: After the user and non-user cohorts were matched no difference 
was found in the means of the propensity scores (p=1.0000). Figures 12b and 13b illustrate that 
the distribution of the scores are very similar between the two groups after matching. The total 
numbers of matched pairs are reported in Table 29. A total of 981 matched pairs were obtained for 
this aim. 
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Table 29:  Pre and post-match cohort counts 
 
 
 Frequency Percent Cumulative 
Frequency 
Cumulative 
percent 
Pre     
Control 2442 66.70 2442 66.70 
Case 1219 33.30 3661 100.00 
Post     
Control 981 50.00 981 50.00 
Case 981 50.00 1962 100.00 
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1: AAPs Users; 0: Non-Users 
 
 
Figure 12a: Distribution of propensity scores before matching 
 
1: AAPs Users; 0: Non-Users 
 
Figure 12b: Distribution of propensity scores after matching  
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1: AAPs Users; 0: Non-Users 
 
Figure 13a: Distribution of propensity scores before matching – Boxplot 
 
1: AAPs Users; 0: Non-Users 
 
Figure 13b: Distribution of propensity scores after matching – Boxplot 
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The absolute standardized differences after matching were calculated and reported in Table 
30. All the differences were less than 10% and hence all the covariates were appropriately balanced 
across the user and non-user cohort. The groups had a mean age of 54 years, comprised mostly of 
white males with disability and approximately seven unique medications the previous year with 
majority of beneficiaries having a diagnosis for schizophrenia and two outpatient visits per year. 
 
Table 30: Baseline characteristics of on-label cohort post-matching 
 
Variable AAPs User 
(N=981) 
AAPs Non-User 
(N=981) 
Standardized 
Difference (%) 
Demographic 
Age (years) 54.47+15.53 (21-98) 54.17+16.68 (21-102) 1.85 
Male 589 (60.04%) 573 (58.41%) 3.32 
Race    
   White  677 (69.01%) 658 (67.07%) 4.15 
   Black  217 (22.12%) 223 (22.73%) 1.47 
   Others 87 (8.87%) 100 (10.19%) 4.51 
Disease Burden 
CCI 0.36+0.98 0.32+0.83  4.83 
No. of medications 7.02+4.79 6.83+6.14 3.46 
ESRD 3 (0.31%) 2 (0.20%) 2.02 
Disability 722 (73.60%) 728 (74.21%) 1.39 
Mental Health Disorders 
Schizophrenia 797 (81.24%) 789 (80.43%) 2.07 
Bipolar Disorder 345 (35.17%) 345 (35.17%) 0 
Resource Utilization 
Inpatient 0.06+0.30 0.07+0.38 2.37 
Outpatient 2.45+4.69 2.24+3.86 4.79 
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Costs: The descriptive statistics of all-cause health care costs of beneficiaries using and not 
using AAPs to treat FDA approved conditions are reported in Table 31. Among non-users the 
highest cost component was inpatient (IP) costs but among AAPs users it was prescription (Rx) 
costs (Figure 14). Outpatient (OP) costs were consistent across the groups with non-users having 
22% of their costs coming from outpatient services. Among users, Medicare paid a mean of $5,052 
per beneficiary in a year and beneficiaries paid an average of $557 per person out-of-pocket. As 
with the off-label cohort, prescription costs were the major out-of-pocket costs for beneficiaries.  
 
 
Figure 14: Breakdown of health care costs by component 
 
Only 113 (5%) of the 1,962 beneficiaries had zero total costs and the cost distribution had 
a right skew distribution. The maximum total cost per beneficiary for the year was $227,900 
(Figure 15) but 99% of beneficiaries had a mean total cost less than $53,000 per beneficiary. The 
mean and median total costs are reported in Table 32.  Mean total costs were found to be 
significantly higher in AAPs users ($7,929) as compared to non-users ($5,402) with a p <0.0001. 
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Even though users had higher mean prescription costs, they had a significantly lower mean 
inpatient cost of $1,012 per beneficiary versus $2,257 per beneficiary among non-users 
(p=0.0019). No differences were found in outpatient costs and these results were robust even in 
the absence of extreme observations (Table 32).  
 
 
Figure 15: Distribution of total costs among beneficiaries in on-label cohort 
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Table 31:  Direct all-cause health care costs by payer 
 
Variable 
 
Mean ($) Lower 
95% CI 
Upper 
95% CI 
Median  
($) 
Minimum 
($) 
Maximum 
($) 
AAPs Non-Users       
Outpatient 
     
  
   Medicare 881 679 1,083 131 0 51,434 
   Beneficiary 282 207 357 24 0 24,101 
   Other payers 7 -4 17 0 0 4,883 
Inpatient        
   Medicare 2,083 1,412 2,754 0 0 212,141 
   Beneficiary 159 124 193 0 0 8,781 
   Other payers 16 -15 46 0 0 15,258 
Prescription        
   Medicare 1,582 1,388 1,777 696 0 51,051 
   Beneficiary 392 358 426 185 0 4,282 
AAPs Users       
Outpatient       
   Medicare 993 730 1,256 116 0 68,032 
   Beneficiary 282 212 353 20 0 19,084 
   Other payers 33 -5 71 0 0 17,069 
Inpatient        
   Medicare 913 596 1,231 0 0 86,806 
   Beneficiary 87 66 109 0 0 2,602 
   Other payers 11 -11 33 0 0 11,021 
Prescription        
   Medicare 5,052 4,794 5,309 3,938 63 26,055 
   Beneficiary 557 525 589 411 3 4,558 
Abbreviation used: CI, Confidence interval 
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Table 32: Mean all-cause health care costs for on-label AAPs users and non-users 
Variable Non-Users Users p-value 
Mean 
($) 
Median 
($) 
SD Mean 
($) 
Median  
($) 
SD Paired 
t-test 
Sign WSR 
Outpatient  1,170 171 4,356 1,308 164 5,350 0.5311 0.5803 0.6459 
Inpatient  2,257 0 11,160 1,012 0 5,338 0.0019 0.0109 0.001 
Prescription  1,975 953 3,448 5,609 4,519 4,324 <0.0001 <0.0001 <0.0001 
Total  5,402 1,858 13,420 7,929 5,660 9,073 <0.0001 <0.0001 <0.0001 
 - Medicare 4,547 1,407 12,307 6,958 4,784 8,011 <0.0001 <0.0001 <0.0001 
Abbreviation used: SD, Standard Deviation; WSR, Wilcoxon Sign-Rank  
 
Resource utilization: The pattern of RU by beneficiaries using AAPs in the presence of 
schizophrenia and bipolar conditions have been described in Table 33. Both users and non-users 
had an average of almost four outpatient visits during the year and did not differ significantly 
(p=0.4826) (Table 34). Users had a significantly fewer inpatient visits during the year (p=0.0008). 
There were non-users who had to use the inpatient services up to nine times during the year while 
the maximum number of inpatient stays a AAPs user had was only four times in the year. Users 
were prescribed more medications during the year in comparison to their non-user counterparts (7 
vs 6 respectively) and also had higher number of medication claims.  
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Table 33:  Annual health care RU among on-label AAPs users and non-users 
Variable Mean Lower 95% CI Upper 95% CI Min Max 
AAPs Non-Users           
Outpatient visits 3.80 3.40 4.19 0 64 
Inpatient visits 0.17 0.13 0.21 0 9 
Medication claims 37.89 35.61 40.17 0 221 
Unique medications 6.86 6.47 7.26 0 37 
AAPs Users      
Outpatient visits 3.85 3.46 4.23 0 58 
Inpatient visits 0.09 0.07 0.11 0 4 
Medication claims 54.99 52.59 57.38 1 245 
Unique medications 7.60 7.28 7.92 1 30 
Abbreviation used: CI, Confidence interval; Min, Minimum; Max, Maximum 
 
Table 34: Differences in RU between on-label AAPs users and non-users 
Variable Difference 
(Users-Non Users) 
SD Lower  
95% CI 
Upper 
 95% CI 
p-value 
Outpatient visits -0.05 8.58 -0.5906 0.4846 0.4826 
Inpatient visits 0.08 0.75 0.0333 0.1277 0.0008 
Medication claims -17.10 51.06 -20.2963 -13.8974 <0.0001 
Unique medications -0.73 7.82 -1.2249 -0.2451 0.0033 
Abbreviation used: CI, Confidence interval; SD, Standard Deviation 
 
 
 
 
 
 
  
 93 
 
Results of the conditional logistic regression models are reported in Table 35. AAPs users 
had 36% lower odds of having an inpatient visit during the year compared to non-users (p=0.0069) 
and had the same odds as a non-user for having an outpatient visit (p=0.1249). More than 10% of 
non-users had at least one inpatient visit during the year versus only 7% of the AAPs users. Even 
though no differences were found in the mean number of outpatient visits between the groups, 
there was a slightly higher number of users (65%) who had at least one outpatient visit when 
compared to the non-users (62%). 
 
Table 35: Adjusted odds ratios of RU between on-label AAPs users and non-users 
Variable Non-User 
 (%) 
User 
 (%) 
OR 
Non-User=Ref 
Lower 
95% CI 
Upper 
95% CI 
p-value 
Outpatient visits 606 (61.77) 638 (65.04) 1.159 0.96 1.4 0.1249 
Inpatient visits 102 (10.40) 68 (6.93) 0.642 0.466 0.886 0.0069 
Medication use 842 (85.83) *         
Abbreviation used: CI, Confidence interval; OR, Odds Ratio 
* Regression not done since 100% medication use in user cohort 
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Specific Aim IVB: Compare mental health RU and costs between Medicare beneficiaries using 
AAPs and those not using AAPs for on-label treatment of mental health conditions. 
 
Costs: AAPs users were found to have significantly higher mean total, prescription and 
inpatient costs (Table 36). The mean total costs among AAPs users were $4,959 versus only $744 
among non-users (p <0.0001). Medicare was paying an average of $4,605 per AAPs user per year 
to cover mental health costs versus only paying $640 per non-user per year. Inpatient and 
prescription costs were also found to be higher among AAPs users as compared to non-users but 
no differences were found for outpatient costs. Prescription cost was the major cost component 
among the users. Among the AAPs agents, risperidone cost the least at approximately $613 per 
beneficiary, while quetiapine cost $6,434 per beneficiary followed by olanzapine and aripiprazole 
at $5,644 per beneficiary and $3,402 per beneficiary respectively.  
Table 36: Mean mental health costs among AAPs users and non-users 
Variable Non-Users Users Difference ($) p-value 
Mean ($) SD Mean ($) SD 
Outpatient  197 1,649 369 2,563 -172 0.0782 
Inpatient 129 1,650 370 2,478 -241 0.0117 
Prescription 418 931 4,221 3,999 -3,802 <0.0001 
Total 744 2,539 4,959 5,555 -4,215 <0.0001 
 - Medicare 640 2,154 4,605 5,129 -3,966 <0.0001 
Abbreviation used: SD, Standard Deviation 
 
 
 
 
 
 95 
 
Resource Utilization: The pattern of mental health RU is described in Table 37. AAPs 
users had significantly higher RU as compared to non-users. Users were prescribed an average of 
two psychotherapeutic medications and filled approximately 21 prescriptions in the year while 
non-users had an average of one medication per year and had an average of only seven claims per 
year. Approximately 27% of users had at least one outpatient visit during the year as compared 
with only 18% of non-users (Table 38). Users had 1.68 times and 2.75 times the odds of non-users 
to have an outpatient and inpatient visit respectively during the follow-up period.   
 
Table 37: Mean annual mental health RU among AAPs users and non-users 
Variable Non-Users Users p-value 
Mean  
Lower  
95% CI 
Upper  
95% CI 
Mean  
Lower  
95% CI 
Upper  
95% CI 
Outpatient visits 1.09 0.83 1.34 1.20 0.98 1.42 0.0105 
Inpatient visits 0.01 0.01 0.02 0.04 0.03 0.06 0.0009 
Medication claims 7.74 7.04 8.43 21.41 20.56 22.26 <0.0001 
Unique medications 0.88 0.82 0.94 2.12 2.05 2.19 <0.0001 
Abbreviation used: CI, Confidence interval 
 
Table 38: Adjusted odds ratios of mental health RU  
Variable Non-User 
(%) 
User 
 (%) 
OR 
Non-User=Ref 
Lower 
95% CI 
Upper 
95% CI 
p-value 
Outpatient visits 177 (18.04) 263 (26.81) 1.683 1.35 2.098 <0.0001 
Inpatient visits 12 (1.22) 33 (3.36) 2.75 1.42 5.324 0.0027 
Medication use 536 (54.64) 981 (100.00) *       
Abbreviation used: CI, Confidence interval; OR, Odds Ratio 
* Regression not done since 100% medication use in user cohort 
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5.4 Specific Aim V 
 
Specific Aim V: Evaluate differences in RU and associated costs in Medicare 
beneficiaries using AAPs and those not using AAPs to treat specific mental health 
conditions. 
Depression: Beneficiaries with a diagnosis of depression and no other mental health 
conditions were identified. Before matching the beneficiaries with depression who used AAPs in 
their treatment and those who did not differed on all baseline characteristics. After matching, 544 
pairs with balanced covariates were obtained as reported in Table 39. The typical beneficiary with 
depression was a 67 year old white female prescribed 13 medications with less than one inpatient 
and four outpatient visits during the year.  
Table 39: Characteristics of beneficiaries with depression before and after matching 
Variable Pre-match Post-match 
  
User 
 N=545 
Non-User 
N=18,995 
ASD 
(%) 
User  
N=544 
Non-User 
N=544 
ASD 
(%) 
Demographic        
Age (%)        
   Mean (years) 67.93+16.67 71.17+13.32 21.47 67.95+16.68 67.28+14.89 4.24 
   <65  37.80 21.67  37.68 38.60   
   65-84 46.42 65.18  46.51 49.63   
   >=85 15.78 13.15  15.81 11.76   
Sex (%)        
   Male  32.84 26.46 14.01 32.72 34.19 3.12 
Race (%)        
   White  75.96 83.97 20.12 75.92 75.55 0.86 
   Black  13.21 8.87 13.88 13.24 11.95 3.88 
   Others 10.83 7.15 12.86 10.85 12.50 5.15 
Disease Burden        
CCI (mean) 0.69+1.40 0.97+1.60 18.32 0.69+1.40 0.82+1.30 9.91 
No. of meds (mean) 12.39+7.28 10.69+6.30 25.1 12.33+7.11 12.87+7.03 7.64 
ESRD (%) 0.18 1.35 13.42 0.18 0.74 8.16 
Disability (%) 39.08 22.45 36.64 38.97 40.81 3.75 
RU        
Inpatient (mean) 0.17+0.60 0.31+0.78 19.79 0.17+0.60 0.23+0.61 9.83 
Outpatient (mean) 4.00+7.02 5.29+7.22 17.78 4.01+7.03 4.07+5.27 0.98 
Abbreviation used: No. of meds, Number of medications; CCI, Charlson Comorbidity Index; ESRD, End-Stage Renal 
Disease; RU, Resource Utilization; ASD, Absolute Standardized Difference  
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Among the 544 patients on AAPs, 433 (80%) had claims for antidepressants in the previous 
year. This could be indicative of patients who are resistant to treatment or relapsing after a 
successful course on antidepressants. In beneficiaries with a diagnosis for depression the mean 
total direct costs were $11,545 among AAPs non-users which was significantly higher than the 
mean costs of $10,804 among AAPs users (p=0.0173) (Table 40). Non-users had a greater number 
of inpatient visits during the year and also had higher inpatient costs compared to AAPs users. On 
the other hand there were no differences in mean number of outpatient visits and mean outpatient 
costs by AAPs use (Table 41). Even though it was expected that users would be prescribed more  
medications, both groups were using an average of 13 medications during the follow up year but 
the costs were significantly greater among the users ($6,152 vs $4,145). 
 
Table 40: Mean all-cause health care costs of beneficiaries with depression 
Variable AAPs Non-Users AAPs Users p-value 
 Mean ($) SD Mean ($) SD 
Outpatient  2,145 5,020 2,123 5,699 0.9442 
Inpatient  5,255 23,847 2,528 12,951 0.0201 
Prescription  4,145 7,511 6,152 6,550 <0.0001 
Total  11,545 26,485 10,804 17,376 0.0173 
Abbreviation used: SD, Standard Deviation 
 
Table 41: Mean all-cause RU in beneficiaries with depression 
Variable AAPs Non-Users AAPs Users p-value 
Mean  SD Mean  SD 
Outpatient visits 4.84 6.34 5.18 9.01 0.4452 
Inpatient visits 0.32 0.78 0.17 0.58 0.0005 
Medication claims 61.99 45.85 82.29 55.01 <0.0001 
Unique medications 12.64 7.09 12.80 7.36 0.6727 
Abbreviation used: SD, Standard Deviation 
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Anxiety and other neurotic disorders: Beneficiaries with ICD-9-CM diagnosis code 300 
including disorders such as anxiety, phobias and obsessive compulsive disorder were identified. 
The balance between the covariates before and after matching are reported in Table 42. After 
matching 126 pairs were identified with balanced covariates. Beneficiaries with anxiety or other 
neurotic disorders were typically 65 years, white, female with mean CCI score of 0.6, 11 unique 
medications and three outpatient visits in a year. 
 
 
Table 42: Characteristics of beneficiaries with anxiety and neurotic disorders before and after 
matching 
 
Variable Pre-match Post-match 
  
User  
N=126 
Non-User 
N=12,812 
ASD 
(%) 
User  
N=126 
Non-User 
N=126 
ASD 
(%) 
Demographic        
Age (%)        
   Mean (years) 65.38+18.02 73.16+11.86 51.01 65.38+18.02 65.53+15.80 0.89 
   <65  43.65 13.98  43.65 40.48   
   65-84 41.27 72.31  41.27 50.00   
   >=85 15.08 13.71  15.08 9.52   
Sex (%)        
   Male  36.51 23.24 29.29 36.51 33.33 6.66 
Race (%)        
   White  84.13 85.47 3.75 84.13 84.92 2.19 
   Black  6.35 8.35 7.68 6.35 4.76 6.93 
   Others 9.52 6.17 12.48 9.52 10.32 2.65 
Disease Burden        
CCI (mean) 0.67+1.48 0.77+1.37 6.76 0.67+1.48 0.63+1.20 2.93 
No. of meds (mean) 11.43+6.98 9.56+5.89 28.88 11.43+6.98 11.37+7.18 0.78 
ESRD (%) 0 0.69 11.76 0 0 0 
Disability (%) 43.65 14.59 67.52 43.65 42.86 1.60 
RU        
Inpatient (mean) 0.21+0.73 0.27+0.70 8.29 0.21+0.73 0.26+0.62 7.00 
Outpatient (mean) 3.23+4.32 4.60+6.34 25.22 3.23+4.32 3.03+3.89 4.83 
Abbreviation used: No. of meds, Number of medications; CCI, Charlson Comorbidity Index; ESRD, End-Stage Renal 
Disease; RU, Resource Utilization; ASD, Absolute Standardized Difference  
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In beneficiaries with diagnosis for anxiety or other neurotic disorders the mean total direct 
costs were $7,250 among AAPs users which was significantly higher than the mean costs of $5,966 
among the AAPs non-users (p=0.0397) as shown in Table 43. Unlike in depression, non-users did 
not differ in their mean inpatient visits or inpatient costs from users. Even though the groups did 
not differ significantly in their mean outpatient visits or number of medications in the follow up 
period (Table 44), the costs did differ significantly. AAPs users had higher prescription costs 
($5,474) in comparison to non-users ($3,030) but had significantly lower outpatient costs ($947 
vs $1,548).  
 
Table 43: Mean all-cause costs of beneficiaries with anxiety and neurotic disorders 
Variable AAPs Non-Users AAPs Users p-value 
 Mean ($) SD Mean ($) SD 
Outpatient  1,548 2,560 947 1,967 0.0253 
Inpatient  1,388 3,963 828 4,087 0.2083 
Prescription  3,030 4,348 5,474 7,429 0.0011 
Total  5,966 7,480 7,250 8,514 0.0397 
Abbreviation used: SD, Standard Deviation 
 
Table 44: Mean all-cause RU in beneficiaries with anxiety and neurotic disorders 
Variable AAPs Non-Users AAPs Users p-value 
Mean  SD Mean  SD 
Outpatient visits 3.86 4.70 3.17 4.95 0.2105 
Inpatient visits 0.16 0.41 0.09 0.44 0.1503 
Medication claims 50.48 36.01 71.02 47.23 <0.0001 
Unique medications 10.85 7.23 11.52 6.18 0.4252 
Abbreviation used: SD, Standard Deviation 
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Dementia: Since there were very few beneficiaries who had dementia in the absence of 
other mental health conditions, all beneficiaries who had a diagnosis for dementia were included 
even if they had other mental health conditions. In order to account for the presence of other mental 
health conditions, was controlled for in the matching. After matching, 279 pairs were identified 
but the groups were not balanced across all covariates (Table 45). Baseline inpatient RU and the 
presence of other mental disorders were not balanced across groups and hence these variables were 
further controlled using GLM regression analyses. 
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Table 45: Characteristics of beneficiaries with dementia before and after matching 
Variable Pre-match Post-match 
  
User 
N=294 
Non-User 
N=1,812 
ASD 
(%) 
User 
N=279 
Non-User 
N=279 
ASD 
(%) 
Demographic       
Age (%)       
Mean (Years) 81.79+9.5 82.95+8.5 12.88 82.38+8.7 82.32+8.4 0.66 
<65 (%) 4.76 2.98  3.58 3.23  
65-84 50.68 50.72  50.18 56.99  
>=85 44.56 46.30  46.24 39.78  
Sex (%)       
Male 20.75 21.58 2.03 20.79 22.58 4.35 
Race (%)       
White 82.99 80.35 6.83 82.80 82.80 0 
Black 12.24 13.52 3.81 12.19 12.54 1.09 
Others 4.76 6.13 6.01 5.02 4.66 1.67 
Disease Burden       
CCI (mean) 1.74+1.73 1.48+1.70 15.40 1.70+1.71 1.81+1.81 6.30 
No. of meds (mean) 12.82+6.4 10.45+6.3 37.35 12.52+6.1 12.56+7.2 0.59 
ESRD (%) 0.34 1.21 9.96 0.36 0.36 0 
Disability (%) 4.76 3.04 8.93 3.58 3.58 0 
Resource Utilization       
Inpatient (mean) 0.58+1.15 0.52+1.02 5.62 0.57+1.16 0.71+1.13 12.22 
Outpatient (mean) 6.07+7.99 6.53+9.23 5.41 6.07+8.10 5.75+6.84 4.25 
Mental Health Disorders (%) 
Depression 67.69 49.94 36.65 66.67 67.03 0.76 
Neurotic 42.86 33.55 19.23 41.22 41.94 1.45 
Psychoactive Substance 5.44 5.30 0.64 5.02 4.30 3.40 
Mental Retardation 2.72 1.32 9.93 1.43 1.43 0 
Other Organic Psychoses 69.39 49.83 40.67 68.1 70.25 4.66 
Other Mental Disorders 10.20 4.91 20.12 9.68 6.45 11.87 
Personality 3.40 1.05 16 2.15 1.08 8.54 
Child and Adolescent 4.42 0.77 23.1 2.15 2.51 2.38 
Child Organic Psychoses 0.34 0.06 6.42 0.36 0 8.48 
Transient Organic 
Psychoses 
4.76 3.97 3.86 4.30 3.58 3.68 
Psychosexual 0 0.06 3.32 0 0 0 
Drug Psychoses 0.34 0.77 5.82 0.36 0 8.48 
Alcoholic Psychoses 0.68 0.77 1.09 0.72 0.36 4.90 
Non-Organic Psychoses 0.34 0.17 3.48 0.36 0.36 0 
Abbreviation used: No. of meds, Number of medications; CCI, Charlson Comorbidity Index; ESRD, End-Stage Renal 
Disease; RU, Resource Utilization; ASD, Absolute Standardized Difference  
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In beneficiaries with diagnosis for dementia in the presence of other mental health 
conditions the mean total direct costs were not significantly different among AAPs non-users 
($18,803) and AAPs users ($16,873) (Table 46). Non-users had a significantly greater number of 
inpatient visits during the year (p=0.0490) and had higher inpatient costs ($11,613 for non-users 
vs. $8,254 for users). On the other hand there were no differences in mean number of outpatient 
visits (Table 47) and mean outpatient costs by AAPs use. On average beneficiaries with dementia 
were prescribed 13 medications per year but AAPs users ($5,018) had significantly higher 
prescription costs than non-users ($3,601).  
 
Table 46: Mean all-cause health care costs of beneficiaries with dementia 
Variable AAPs Non-Users AAPs Users p-value 
 Mean ($) SE Mean ($) SE 
Outpatient  3,648 348 3,528 344 0.8050 
Inpatient  11,613 1,322 8,254 1,153 0.0490 
Prescription  3,601 161 5,018 224 <0.0001 
Total  18,803 1,335 16,873 1,265 0.2880 
Abbreviation used: SD, Standard Deviation 
  
Table 47: Mean all-cause RU in beneficiaries with dementia 
Variable AAPs Non-Users AAPs Users p-value 
Mean  SE Mean  SE 
Outpatient visits 8.32 0.57 8.21 0.57 0.887 
Inpatient visits 0.99 0.08 0.72 0.07 0.0170 
Medication claims 75.31 2.44 88.60 2.89 <0.0001 
Unique medications 13.02 0.36 13.36 0.37 0.5170 
Abbreviation used: SD, Standard Deviation 
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Schizophrenia: Beneficiaries with a diagnosis of schizophrenia and no other mental health 
conditions were identified. Before matching the beneficiaries with a schizophrenia diagnosis had 
different baseline characteristics based on their AAPs use. Beneficiaries prescribed AAPs were a 
younger cohort with mean age of 53 years as compared to the non-users with a mean age of 70 
years. After matching, 622 pairs of beneficiaries with schizophrenia and no other mental health 
conditions were identified (Table 48). The typical beneficiary with schizophrenia was a 56-year-
old white male with a mean CCI score of 0.32, prescribed six medications and an average of two 
outpatient visits during the year.  
 
Table 48: Characteristics of beneficiaries with schizophrenia before and after matching 
Variable Pre-match Post-match 
  
User 
 N=765 
Non-User 
N=1,665 
ASD 
(%) 
User  
N=622 
Non-User 
N=622 
ASD 
(%) 
Demographic        
Age (%)        
   Mean (years) 52.90+16.02 69.81+17.10 102.04 56.10+15.52 55.89+16.29 1.31 
   <65  75.56 33.27  70.10 69.94   
   65-84 21.05 45.11  25.72 25.56   
   >=85 3.40 21.62  4.18 4.50   
Sex (%)        
   Male  67.97 47.21 42.98 64.15 65.27 2.35 
Race (%)        
   White  64.44 72.13 16.58 64.47 63.67 1.67 
   Black  25.23 19.58 13.58 25.40 25.88 1.1 
   Others 10.33 8.29 7.02 10.13 10.45 1.06 
Disease Burden        
CCI (mean) 0.27+0.77 0.85+1.53 48.12 0.32+0.83 0.32+0.78 0.20 
No. of meds (mean) 6.55+4.63 7.76+6.04 22.53 6.56+4.64 6.40+6.01 3.08 
ESRD (%) 0.26 1.62 14.12 0.32 0.32 0 
Disability (%) 76.21 33.63 94.67 70.74 70.26 1.06 
RU        
Inpatient (mean) 0.05+0.28 0.27+0.78 38.70 0.06+0.31 0.05+0.29 3.75 
Outpatient (mean) 2.11+4.46 4.24+6.89 36.73 2.35+4.86 2.42+5.36 1.38 
Abbreviation used: No. of meds, Number of medications; CCI, Charlson Comorbidity Index; ESRD, End-Stage Renal 
Disease; RU, Resource Utilization; ASD, Absolute Standardized Difference  
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In beneficiaries with diagnosis for schizophrenia the mean total direct costs were $4,999 
among AAPs non-users which was significantly lower than the mean costs of $7,989 among the 
AAPs users (p<0.0001) (Table 49). Even though the groups did not differ in their outpatient and 
inpatient costs AAPs users had a significantly higher prescription costs ($5,753) which was the 
major component of total all-cause health care costs. Even though the AAPs users had higher  
prescription costs they were prescribed on average seven medications during the year which was 
not significantly different from the number of medications non-users were prescribed (p=0.1244) 
(Table 50).  
 
Table 49: Mean all-cause health care costs of beneficiaries with schizophrenia 
Variable AAPs Non-Users AAPs Users p-value 
 Mean ($) SD Mean ($) SD 
Outpatient  1,078 4,011 1,227 5,323 0.5788 
Inpatient  2,016 12,784 1,009 5,780 0.068 
Prescription  1,905 2,888 5,753 4,542 <0.0001 
Total  4,999 14,452 7,989 9,345 <0.0001 
Abbreviation used: SD, Standard Deviation 
 
Table 50: Mean all-cause RU in beneficiaries with bipolar disorder 
Variable AAPs Non-Users AAPs Users p-value 
Mean  SD Mean  SD 
Outpatient visits 3.64 6.35 3.81 6.10 0.6227 
Inpatient visits 0.13 0.55 0.09 0.41 0.1727 
Medication claims 36.73 36.17 53.69 37.87 <0.0001 
Unique medications 6.40 5.81 6.84 4.68 0.1244 
Abbreviation used: SD, Standard Deviation 
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Bipolar disorder: Beneficiaries with a diagnosis of bipolar disorder and no other mental 
health conditions were identified from the population of interest. The AAPs users and non-users 
differed significantly in their mean age, mean CCI score, mean number of medications, outpatient 
and inpatient visits among others (Table 51). A total of 176 pairs of bipolar patients were identified 
after matching and all covariates except race were balanced at baseline, hence race was controlled 
for in the regression. The typical beneficiary with bipolar disorder was a 52-year-old white female 
with a mean CCI score of 0.4, eight unique medications and two outpatient visits over the baseline 
period. 
Table 51: Characteristics of beneficiaries with bipolar disorder before and after matching 
Variable Pre-match Post-match 
  
User  
N=195 
Non-User 
N=606 
ASD 
(%) 
User  
N=176 
Non-User 
N=176 
User 
N=195 
Demographic        
Age (%)        
   Mean (Years) 50.00+15.54 59.94+16.59 61.78 51.68+14.96 51.94+16.75 1.65 
   <65 (%) 78.46 51.16  76.14 76.14   
   65-84 18.97 45.54  21.02 21.59   
   >=85 2.56 3.3  2.84 2.27   
Sex (%)        
   Male  43.59 45.54 3.93 46.59 47.73 2.28 
Race (%)        
   White  82.05 85.48 9.3 82.39 86.93 12.64 
   Black  9.23 10.07 2.83 10.23 6.25 14.5 
   Others 8.72 4.46 17.25 7.39 6.82 2.21 
Disease Burden        
CCI (mean) 0.39+0.97 0.55+1.15 15.27 0.39+1.00 0.40+0.98 1.72 
No. of medications 
(mean) 
8.54+5.42 7.74+5.80 14.27 7.82+4.80 7.75+6.45 1.2 
ESRD (%) 0 0.17 5.75 0 0 0 
Disability (%) 78.97 52.81 57.43 76.7 77.27 1.35 
Resource Utilization        
Inpatient (mean) 0.09+0.32 0.15+0.53 13.73 0.09+0.33 0.09+0.36 0 
Outpatient (mean) 2.53+3.76 3.23+4.83 16.23 2.51+3.83 2.45+3.51 1.54 
Abbreviation used: No. of meds, Number of medications; CCI, Charlson Comorbidity Index; ESRD, End-Stage Renal 
Disease; RU, Resource Utilization; ASD, Absolute Standardized Difference  
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In beneficiaries with diagnosis for bipolar disorder with no other mental health conditions 
the mean total direct costs were significantly higher among the AAPs users ($7,673) as compared 
to the non-users ($4,477) (Table 52). This difference in cost was mainly driven by prescription 
costs since the inpatient and outpatient costs did not differ by AAPs use. AAPs users had a mean 
prescription cost of $5,011 per beneficiary in comparison to $2,321 per non-user (p<0.0001). The 
beneficiaries did not differ in their outpatient and  inpatient visits (Table 53) but AAPs users were 
prescribed on average more unique medications in the follow up period as compared to the non-
users (p<0.0001). 
 
Table 52: Mean all-cause health care costs of beneficiaries with bipolar disorder by AAPs use 
Variable AAPs Non-Users AAPs Users p-value 
 Mean ($) SE Mean ($) SE 
Outpatient  1,467 283 1,297 244 0.6460 
Inpatient  737 324 1,328 458 0.2960 
Prescription  2,321 314 5,011 683 <0.0001 
Total  4,477 503 7,673 865 0.0010 
Abbreviation used: SD, Standard Deviation 
 
Table 53: Mean all-cause RU in beneficiaries with bipolar disorder 
Variable AAPs Non-Users AAPs Users p-value 
Mean  SE Mean  SE 
Outpatient visits 3.22 0.34 3.52 0.37 0.5530 
Inpatient visits 0.07 0.02 0.11 0.02 0.2260 
Medication claims 36.00 2.40 56.00 3.72 <0.0001 
Unique medications 7.72 0.42 9.38 0.51 0.0130 
Abbreviation used: SD, Standard Deviation 
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5.5 Sensitivity Analyses 
 
1) In Specific Aim III, AAPs users included both existing users and new users of AAPs since 
sample size of using only new AAPs users was a concern. In this sensitivity analysis, only 
beneficiaries who were new AAPs users were included; that is, any beneficiary with AAPs 
prescriptions in 2008 were excluded. The users and non-users were matched and all covariates 
were balanced across the two groups. Even though mental health visits and costs remained robust 
with AAPs users having more outpatient, prescription and total costs (Table 55), there were some 
changes in all-cause costs. Outpatient costs and visits, which were not significantly different 
among users and non-users in Specific Aim IIIA, showed that AAPs users had significantly higher 
outpatient costs and visits (Table 54). Similarly, inpatient costs between the users and non-users 
had no significant differences, which was a change from non-users having more inpatient costs in 
Specific Aim IIIA. These results in combination with the mental-health visits may be indicative of 
higher RU and costs among new AAPs users.  
 
Table 54: All-cause costs and RU among new off-label AAPs users and non-users 
 
Variable AAPs Non-Users AAPs Users p-value 
 Mean  SD Mean  SD 
Cost ($)      
Outpatient  2,945 6,813 3,675 7,582 0.0010 
Inpatient  8,870 26,197 6,969 16,129 0.1448 
Prescription  3,798 5,549 5,890 5,659 <0.0001 
Total  15,613 29,917 16,534 20,756 0.4099 
RU      
Outpatient visits 6.39 8.16 6.41 8.90 0.0132 
Inpatient visits 0.58 1.15 0.41 0.96 0.0390 
Medication claims 67.50 49.14 84.78 50.27 <0.0001 
Unique medications 13.08 7.82 13.22 7.27 <0.0001 
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Table 55: Mental health costs and RU among new off-label AAPs users and non-users 
 
Variable AAPs Non-Users AAPs Users p-value 
 Mean  SD Mean  SD 
Cost ($)      
Outpatient  183 777 663 3,143 <0.0001 
Inpatient  771 3,113 1,149 4,326 0.0226 
Prescription  45 93 233 220 <0.0001 
Total  1,000 3,276 2,045 5,323 <0.0001 
RU      
Outpatient visits 0.53 1.51 1.36 4.20 <0.0001 
Inpatient visits 0.09 0.33 0.12 0.44 0.1323 
Medication claims 6.88 8.05 18.90 12.44 <0.0001 
Unique medications 1.07 1.06 2.61 1.27 <0.0001 
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2) In this sensitivity analyses all aripiprazole users were excluded so that any depression AAPs 
users in this cohort is truly an off-label user. The users and non-users were matched and all 
covariates were balanced across the two groups. As in the previous sensitivity analysis, the mental 
health costs and RU remained robust despite the change in the included cohort (Table 57). 
Interestingly, in all-cause costs, outpatient, inpatient, prescription, and total costs were now 
significantly higher among AAPs non-users (Table 56). In Specific Aim IIIA, only inpatient costs 
and prescription costs were higher among non-users while no differences were observed in 
outpatient and total costs.  
 
 
Table 56: All-cause costs and RU among off-label AAPs users and non-users excluding 
aripiprazole users 
 
Variable AAPs Non-Users AAPs Users p-value 
 Mean  SD Mean  SD 
Cost ($)      
Outpatient  2,714 5,559 2,506 5,786 0.0030 
Inpatient  7,327 21,752 4,709 13,957 <0.0001 
Prescription  3,933 6,654 5,551 4,999 <0.0001 
Total  13,975 24,716 12,766 17,483 0.0390 
RU      
Outpatient visits 6.39 8.16 6.41 8.90 0.0368 
Inpatient visits 0.58 1.15 0.41 0.96 <0.0001 
Medication claims 67.50 49.14 84.78 50.27 <0.0001 
Unique medications 13.08 7.82 13.22 7.27 0.3937 
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Table 57: Mental health costs and RU among off-label AAPs users and non-users excluding 
aripiprazole users 
 
Variable AAPs Non-Users AAPs Users p-value 
 Mean  SD Mean  SD 
Cost ($)      
Outpatient  234 1,362 408 2,142 <0.0001 
Inpatient  645 3,135 867 4,134 0.0242 
Prescription  41 87 196 198 <0.0001 
Total  920 3,475 1,472 4,694 <0.0001 
RU      
Outpatient visits 0.58 1.67 0.97 3.06 <0.0001 
Inpatient visits 0.08 0.31 0.09 0.39 0.0925 
Medication claims 6.79 8.57 21.53 12.59 <0.0001 
Unique medications 1.00 1.05 2.41 1.18 <0.0001 
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Chapter 6: Discussion 
 
This chapter discusses the results of the Medicare study and describes the strengths and limitations 
of the study. 
6.1 Specific Aim II 
 
The sample used in the analysis was Medicare beneficiaries prescribed AAPs in 2008, 2009 
and 2010. Approximately 3.2% of the Medicare beneficiaries were prescribed AAPs each year and 
the prevalence remained constant across the three years. The typical AAPs users were 64-year-old 
white females, almost half of them had disability and less than 1% had ESRD. Even though the 
socio-demographic characteristics are similar to published literature in the same population 
(Driessen et al., 2016) the prevalence of AAPs use in this population (3.2%) is lower than in the 
published literature (8%), probably because our study used a more conservative definition of AAPs 
user. We defined a user as a beneficiary who had at least two claims within 60 days for one AAPs 
agent while Driessen et al. defined it as a beneficiary with one AAPs claim. Majority of the AAPs 
users were prescribed quetiapine (43%) followed by risperidone (34%) while ziprasidone was the 
least commonly prescribed AAPs (7%).  
The prevalence of off-label use among AAPs users has been persistent across 2008 to 2010. 
The prevalence was 36.7% in 2008 and 36.5% in 2010. The rate of off-label use is lower than that 
reported by Driessen et al. in a Medicare population, but our study used the more conservative 
definition of AAPs use. Driessen et al. reported a decline in off-label use from 51% to 45% from 
2008 to 2010. The typical off-label AAPs user was a 70-year-old white female without a disability 
while the typical on-label AAPs user was 60-year-old white female with disability and the socio-
demographic factors are in accordance to published results (Driessen et al., 2016). Driessen et al. 
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also reported off-label users to be older (mean age = 66 years) compared to on-label users (mean 
age = 52 years) and were typically white females.  
The prevalence of off-label use among 18-64 year old AAPs users is 24% which is almost 
comparable to the 19.5% prevalence of off-label use in a similar age group reported by Citrome et 
al. (2013). The prevalence of off-label use among AAPs users greater than 65 years was 49%, this 
is lower than the estimates reported by Kamble et al. (86%) and Levinson (83%) in nursing home 
residents (Kamble et al., 2010; Levinson, 2011). The difference in the findings between our study 
and earlier reports within the same age groups could be explained due to the differences in the 
health of the population included in the studies. Our study focused on community dwelling 
Medicare beneficiaries whereas the previous studies reported off-label use in Medicare 
beneficiaries residing in nursing homes. A majority of these patients were diagnosed with dementia 
requiring constant care and this could explain the higher rates of off-label use.  
Even though the prevalence of off-label use has not dramatically shifted over the three 
years, there have been noticeable changes in the prevalence of the mental health conditions 
associated with off-label use. In 2008, 31% of the off-label users had dementia or related other 
organic psychosis: this decreased to 24.8% by 2010. Similarly, beneficiaries with depression 
decreased from 53.8% to 48.6% and beneficiaries with neurotic and anxiety disorders decreased 
slightly from 35.9% to 32.8%. These changes could be reflective of published literature in 2007 
by AHRQ on the evidence for safety and efficacy of off-label AAPs use (AHRQ, 2007). Despite 
the FDA black box warning due to safety issues and only moderate to low evidence for its efficacy 
in dementia (Schneider et al., 2006); it continues to be one of the top three reasons for off-label 
use. Similarly, for patients with SSRI resistant depression, there was only modest evidence to 
support augmentation of antidepressant therapy with AAPs which could be driving the slight 
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decrease in patients with depression. The updated AHRQ review in 2011 states that there may be 
new evidence to show that AAPs have efficacy as augmentation therapy in depression and 
quetiapine may even be effective as monotherapy (Maglione et al., 2011) which could lead to 
differences in prescribing patterns compared to results observed in this study.  
Although off-label prescribing is a prevalent and common practice, it is particularly 
prevalent in the AAPs class of drugs. Our study found that 37% of AAPs use is in the complete 
absence of an FDA approved indication; that is a lower estimate than previously published. This 
could be due to federal steps such as the black box warning and the litigations. Even though this 
estimate is lower than expected, it is still of concern due to the presence of risk of adverse events 
and lack of evidence of effectiveness. Often physicians are faced with no other choice than to 
prescribe AAPs due to the patient’s perceived need for treatment and in the face of treatment 
resistant patients. It also poses a dilemma to the payers since they have to balance the needs of the 
prescriber and patients, with safety concerns and cost issues. It may be worthwhile to educate 
patients and physicians in order to change their beliefs about the efficacy of AAPs in off-label 
treatment. Patients may also need to be educated about expected signs and symptoms of certain 
conditions such as neuropsychiatric symptoms of dementia to help them differentiate abnormal 
versus expected symptoms. Educating patients about what is expected could better help them 
prepare for these conditions rather than resorting to pharmacotherapy at the onset. 
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6.2 Specific Aim III 
 
The purpose of this aim was to compare health care RU and costs between off-label AAPs 
users and non-users with mental health diagnoses in a Medicare population. The study results 
found that AAPs users were more likely than non-users to use an outpatient facility for mental 
health visits. AAPs users were also more likely to have mental health medications and claims. 
Total mental health costs were significantly higher among AAPs users ($1,545) in the 12-month 
follow up as compared to non-users ($1,057). Medicare paid an additional $396 per beneficiary 
per year for mental health costs for off-label users. These findings are similar to the study by Del 
Paggio et al.which reported an increase in mental health medication and outpatient costs after 
initiation with olanzapine but also reported a decrease in inpatient and emergency costs (Del 
Paggio et al., 2002). This difference from our study could be due to the indigent population in the 
Del Paggio study who had to be severely and persistently ill to qualify for the publicly funded 
program whereas our study population was community dwelling patients.  
Upon examining all-cause RU and costs, AAPs users had a significantly lower number of 
inpatient visits and costs. AAPs users had 34% lower odds of having an inpatient visit in 
comparison to non-users and AAPs non-users incurred an incremental cost of $2,104 per 
beneficiary per year for inpatient visits. These findings are similar to the results reported by Al-
Zakwani et al. using data from a private health plan which reported that AAPs users had fewer 
inpatient admissions after initiation of AAPs as compared to baseline (Al-Zakwani et al., 2003). 
Al-Zakwani et al. reported lower outpatient visits in their population but our study failed 
to show a difference in the number of outpatient visits and costs between AAPs users and non-
users. This could be reflective of the different population in the two studies. Our study focused on 
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a Medicare population that comprised mostly an older population with mean age of 66 years who 
may have scheduled more outpatient visits for increased monitoring of drug effects and chronic 
condition treatment but the population in the study was a young cohort form a private health plan. 
The different reimbursement policies between private plans and Medicare could also affect these 
differences.  
Our results also indicate that the rate of RU is sensitive to whether the AAPs is newly 
initiated or not. Upon examining RU in off-label AAPs users who had newly initiated the AAPs 
in 2009, AAPs users had significantly higher outpatient costs compared to non-users which was 
similar to the results we obtained in the MEPS study which concluded that AAPs users had higher 
outpatient costs. Inpatient costs had also gone from being higher among non-users to being not 
different from AAPs users. These results indicate that in new AAPs users, RU is higher among 
users as compared to non-users. 
The Del Paggio et al. study is the only one that assessed mental health prescription costs 
and our study reflected similar results costs (Del Paggio et al., 2002). Prescription costs were 
significantly higher among AAPs users than non-users irrespective of whether they were all-cause 
or mental health. AAPs are generally an expensive class of medications and the average cost of 
some of the AAPs can be a financial burden on patients. Additionally, during the study period 
from 2008-2010 all of the AAPs of interest were available only as brand name products except 
risperidone which became available as generic during the study period. Since some of these agents 
are now available as generic, AAPs costs may show a downward trend in the future. Prescription 
costs can be a financial burden on both Medicare and on beneficiaries. Among AAPs users the 
highest share of costs for Medicare (average $4,855 per person per year) and beneficiaries (average 
$1,066 per person per year) was attributed to prescription costs. The additional prescription costs 
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can be considered cost-effective if treatment with AAPs adequately decreases other health care 
costs such as inpatient and emergency costs or if they are clinically effective. In this study, 
inpatient costs were found to be the major contributing factor towards total costs among non-users 
and a smaller component of total costs in AAPs users. This seems to indicate an association 
between AAPs use and lower inpatient costs. 
  
6.3 Specific Aim IV 
 
The objective of this aim was to compare RU and costs associated with Medicare 
beneficiaries who are using AAPs for on-label treatment of schizophrenia and bipolar disorder to 
non-users with the same indications. The study results show AAPs users to have significantly 
higher mental health inpatient, prescription and total costs in comparison to their AAPs non-user 
counterparts. There was an additional cost of $718 per beneficiary for total mental health costs and 
Medicare spent three times the amount on a beneficiary using AAPs than a non-user during the 
follow up period. AAPs users also had significantly higher mental health RU. The odds of having 
at least one mental health outpatient and inpatient visit were 68% and 175% higher for AAPs users 
than non-users. Revicki et al. reported higher mental health outpatient costs among AAPs users in 
a bipolar population and He et al. reported higher number of psychiatric outpatient visits among 
AAPs users in a schizophrenic population, which are similar trends to our study results (Revicki 
et al., 2003, He et al., 2015).  
Prescription costs continue to be the major factor driving total costs among users. It was 
the main cost component among on-label AAPs users during the follow-up period while inpatient 
costs are the main component among non-users. AAPs users had higher all-cause and mental health 
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prescription costs which was similar to the findings by He et al. (He et al., 2015). He et al. reported 
AAPs users had  a mean cost of $438 per beneficiary which is slightly higher than our findings of 
$356 per beneficiary. Inpatient costs follow a different pattern from what is reported by Guo et al. 
(Guo et al., 2007). Our study findings show all-cause inpatient costs to be significantly lower 
among AAPs users compared to non-users. This finding was robust even after accounting for 
skewed distribution or exceptionally high inpatient costs for a few beneficiaries. Guo et al. reported 
that AAPs users had higher inpatient and emergency costs but their comparison group was 
beneficiaries using mood stabilizers for the treatment of bipolar disorder unlike our comparison 
group that included beneficiaries who may have had non-antipsychotic treatment but also includes 
those with no treatment at all.  
An interesting pattern also exists among the mental health costs between off-label and on-
label AAPs user cohort from Specific Aim III and IV. Off-label users had comparatively higher 
inpatient, outpatient and total costs even though both cohorts were using AAPs to treat mental 
health conditions. The major difference between the treatments in the two groups is the level of 
evidence. While on-label use is supported in literature by strong to moderate evidence, most off-
label use only has moderate to low evidence (Maglione et al., 2011). This could be further reason 
to believe that off-label use of AAPs in the treatment of mental health conditions that is not 
supported by evidence does not benefit the health care system from a payer perspective because 
of increased RU and from a patient perspective since they are exposed to the adverse effects of 
these agents. Therefore, the benefit of initiating these agents for off-label treatment should be 
weighed against the risks and should be reserved only if no other options are viable. 
The typical off-label user is a 66-year-old white female in contrast to a typical on-label 
user who is a 52-year-old white male. It is an interesting phenomenon that older patients are more 
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likely to be prescribed AAPs in the absence of an FDA approved indication and without strong 
clinical evidence to support the use. This is of concern since elderly patients are more susceptible 
to the adverse effects of these agents. Off-label AAPs users also had higher number of comorbid 
conditions as seen by an average CCI of 0.9 whereas the CCI is only 0.32 among on-label users 
which could also explain the higher health care costs among off-label users. Off-label users also 
have higher medication burden with an average of 13 medications per beneficiary in comparison 
to the 7 medications per on-label user. 
 
6.4 Specific Aim V 
 
In this aim the RU and costs of AAPs users treated for specific mental health conditions 
were compared to their non-user counterparts.  
Depression: Among patients with depression, the mean number of all-cause inpatient visits 
and costs were significantly lower in AAPs users than non-users. The higher prescription costs 
among users were offset by their lower inpatient costs leading to a significantly lower total health 
care costs. Interestingly both users and non-users had similar medication burden of approximately 
13 medications per beneficiary but users had significantly higher costs compared to non-users. 
AAPs are increasingly used to treat patients with depression over the years especially with some 
of AAPs receiving FDA approval for the same. There is moderate evidence to support the use of 
aripiprazole, quetiapine and risperidone as augmentation therapy and quetiapine as monotherapy 
therefore treatment with these agents should only be considered in anti-depressant treatment 
resistant patients (Maglione et al., 2011).  
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Anxiety and neurotic disorder: In patients with anxiety, neurotic and other somatoform 
disorders AAPs users had numerically lower inpatient and outpatient costs but it did not achieve 
significance. Due to the significantly large prescription costs, total health care costs were 
significantly higher in AAPs users compared to non-users. This pattern could be of key interest to 
payers such as Medicare and private health plans since they have to incur additional costs on AAPs 
users but it could potentially increase the patients’ quality of life and decrease downstream costs 
if they are able to avoid multiple inpatient and outpatient visits. The presence of moderate to strong 
evidence for the use of risperidone and quetiapine in OCD and anxiety respectively, warrants the 
consideration of use of AAPs in this population. Even though use of AAPs in this cohort is off-
label, it could be cost-effective to treat these patients with AAPs if the excess prescription costs 
are accompanied by positive clinical changes. Due to the nature of our data, we were unable to 
capture clinical effectiveness in our study but future research can focus on examining the relation 
between costs and clinical effectiveness.  
Dementia: Off-label use of AAPs in elderly patients with dementia is controversial due to 
the increased risk of mortality. Despite significantly higher prescription costs in AAPs users, non-
users had higher total costs ($18,803 vs $16,873) than users. Even though this failed to show any 
statistical significance, non-users incurred approximately $2,000 additional per person not treated 
with AAPs. This might reflect the severity of patients with no other treatment options. There could 
be non-users who are severely ill but not prescribed medications due to the risk profile or lack of 
evidence of efficacy and who seek emergent or inpatient care for their medication needs. Strong 
evidence for the efficacy of AAPs in the treatment of behavioral symptoms of dementia might 
explain the practice of prescribing AAPs to patients with dementia despite the associated risks 
(Maglione et al., 2011). Therefore, it is once again imperative to consider not only the costs 
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associated with AAPs user but also clinical changes in the patients. Patients who have no other 
treatment options may very well respond to AAPs under careful monitoring and supervision of 
practitioners. Schizophrenia: Patients with schizophrenia using AAPs had significantly higher 
prescription and total costs compared to patients not treated with AAPs. AAPs are the first line of 
treatment for patients with schizophrenia and all the agents have been FDA approved for this 
indication. Since there are no other treatment options, the higher costs of the drugs can still be 
cost-effective as patients achieve clinical stability. 
Bipolar disorder: Beneficiaries with bipolar disorder showed very similar trends wherein 
AAPs users had higher prescription and total costs compared to non-users but no differences were 
observed in outpatient and inpatient costs. Guo et al. (2007) discussed in their study about how 
despite sufficient evidence to support the use of AAPs in bipolar patients it might be worthwhile 
to consider initiating other therapies such as mood stabilizers which are associated with lower RU 
and costs. Since our study did not show either cohort to have significantly higher inpatient or 
outpatient costs, but showed significantly higher prescription costs, it may be of economic value 
to consider other pharmacotherapy which are shown to be equally effective but cheaper in this 
population.  
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6.5 Strengths and Limitations 
 
To the best of our knowledge, this is the first study that has evaluated RU and costs 
associated with off-label use of AAPs in a Medicare population. Published literature has primarily 
studied the effects on a younger population even though there is evidence of adverse effects of 
AAPs in the elderly population. Further, ours is the first study to use Medicare claims data, which 
is a public payer, to evaluate off-label use. Studies have mostly evaluated costs from a private 
payer perspective and this study provides estimates of RU and costs from the perspective of a 
public payer. In addition, recall and self-report bias was reduced since administrative claims data 
was used instead of other sources like self-reported surveys.  
The study also used sound methodologic design to control for observed variables. We 
identified a control group and used propensity score matching to balance covariates across the 
study groups. This reduced the potential for bias. In groups where propensity score matching did 
not balance all covariates between the two groups, generalized linear models were used to control 
for any unbalanced covariate. Having three years of data also enabled a longer duration of baseline 
and follow-up (12 months). The study also used conservative methods when possible to capture 
the true effects. For example, to be diagnosed with a medical condition, the beneficiary had to have 
two outpatient claims instead of just one claim. Similarly, to be defined as AAPs user, the 
beneficiary had to have at least two claims one to 60 days apart for the same antipsychotic. 
The study, however, has several limitations. First, the secondary nature of the dataset 
imposes certain assumptions. We assume that patients with claims for AAPs are taking the 
medication as prescribed. We also assume that the information recorded in the claims dataset is 
accurate. Databases may be subject to miscoding which could lead to inaccurate and biased results. 
There may also be underrepresentation of certain diagnoses since diseases with greater severity 
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could be listed under primary diagnosis (Brookhart, 2014). For example, a patient’s primary 
diagnosis code reports myocardial infarction but his depression diagnosis is not coded. Second, 
we cannot determine which medical condition the prescribed drug is treating. Therefore, we were 
unable to determine if AAPs were used in off-label or on-label treatment in beneficiaries with 
multiple mental health conditions. We addressed this limitation by creating mutually exclusive 
groups of beneficiaries who were using AAPs for off-label treatment or on-label treatment by 
excluding those beneficiaries who had indications for both an off-label and on-label condition. By 
creating mutually exclusive groups, we ascertain that the users are using the drug only in the 
presence of the particular condition even if we cannot ascertain that the drug was used for that 
condition. In the final Specific Aim we also created mutually exclusive groups by specific disease 
state to identify beneficiaries who were using AAPs only in the presence of diagnosis claims for 
depression, anxiety, schizophrenia or bipolar disorder. Third, even though matching was 
performed to remove differences among the groups due to observed variables, the study was not 
able to control for unobserved differences such as patient specific factors including patient 
preferences. These predictors could have influenced the choice of AAPs in the treatment of certain 
conditions and could be potentially influencing the results. For example, patients intolerable to 
adverse effects of antidepressants such as decreased libido and disturbed sleep cycles may prefer 
initiation of AAPs. Fourth, since we used claims data and not electronic health records we were 
unable to obtain past medical history, which can influence RU and costs. We tried to address this 
limitation by using 12 months of baseline period to capture comorbid conditions using claims data. 
Even though we addressed this limitation in the best possible manner using claims data, we have 
to recognize that only conditions for which the patient had an inpatient or outpatient visit was 
captured in their baseline. Therefore, any conditions for which the beneficiary did not seek 
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treatment during the study period were not captured. Fifth, even though we tried to control for 
severity of disease by including the baseline RU in the propensity model, there may still be 
underlying differences among the AAPs users and non-users due to the level of severity of disease 
which is beyond the researcher’s control. Sixth, due to limited funding the study was limited to 
institutional costs which were obtained from inpatient, outpatient and prescription costs. We did 
not include the carrier file claims in this study therefore the RU and costs estimated in this study 
do not reflect physician office-based outpatient costs. Similarly, other costs, which may be 
estimated from other Medicare files such as home health and hospice, were also not included in 
this study. Due to the lack of these components, we were unable to estimate the total RU associated 
with off-label use and the study focused only on institutional costs. Additionally, since we did not 
have the carrier file, we were restricted to identifying chronic health and other mental conditions 
by only using inpatient and institutional outpatient claims. In order to restrict this limitation, we 
used the Chronic Conditions and Other Chronic Conditions files to identify diagnoses codes that 
may not have appeared in the claims during the 3-year study period.  
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6.6 Conclusions and Future Research 
 
Off-label use of AAPs is an important public health issue that has gained attention the last 
few years. As a class of drugs, AAPs carry their own adverse risk profile even as they are used to 
treat mental health conditions for which no other treatments exist or to treat patients who have 
become resistant to other treatments. To the best of our knowledge no other study has examined 
the RU and costs in off-label AAPs users using nationally representative data or Medicare data. 
The objective of the pilot study was to examine patterns of RU among off-label AAPs users 
in a nationally representative population. Patients using AAPs for off-label treatment of mental 
health conditions had higher all-cause utilization of any resource, office-based provider visits, and 
hospital inpatient visits per year compared to those not using AAPs in off-label treatment and their 
total costs including prescription and office-based outpatient costs were significantly higher.  
The objective of the second study was to evaluate the prevalence of off-label use in 
Medicare beneficiaries and to compare RU between off-label AAPs users and non-users. Of the 
total beneficiaries, 3.2% used AAPs and 36% of these were off-label users. Some of the most 
common indications of off-label use were depression, anxiety and dementia. Total mental health 
costs, outpatient costs and medication costs were higher among off-label AAPs users but all-cause 
inpatient costs were higher among non-users.  
Off-label prescribing of AAPs continued to be a prevalent practice though it affects less 
than half of all AAPs users. For all-cause RU and costs, we had different results from the MEPS 
study and the Medicare study: among MEPS respondents AAPs users had higher RU and costs but 
Medicare AAPs users had lower RU and costs. This difference in results could be due to the 
difference in the population (younger vs. older), design (cross-sectional vs. cohort), study methods 
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(regression vs. matching), or data (self-report vs. administrative claims). Medicare study also 
showed that AAPs users had higher RU and costs associated with mental health visits and 
prescription cost was the main factor driving total costs. This study points to some association 
towards AAPs use and increased costs. If the increased costs from medications can be offset by 
decreased inpatient or outpatient costs or is accompanied with clinical effectiveness then off-label 
treatment with AAPs can be recommended as a cost-effective option.  
Future research should examine the RU patterns based on the evidence supporting the off-
label treatment. Cohorts of patients with off-label but supported use and off-label but unsupported 
use should be identified and compared. Future research should also focus on examining the 
association between RU and clinical outcomes. For example, does off-label use of AAPs improve 
clinical outcomes and improve quality of life despite the higher RU? This would help identify cost-
effectiveness of using AAPs for off-label use. Future researchers can also assess the effects of 
duration of therapy and adherence on long term RU and costs.  
As we move forward, it will be interesting to observe the RU pattern in this population in 
the after-effects of the CMS partnerships. The results of this study will serve as the baseline as we 
try to identify if utilization and costs have increased or decreased as a direct effect of these changes.  
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